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Respiratory Syncytial Virus (RSV)is one of the most common causes of acute lower 
respiratory tract infection in humans that can cause severe infections in infants and the 
elderly. It is estimated that annually 33 million lower respiratory tract infections in children 
were associated with RSV worldwide. However, in the US alone there were 75000-125,000 
hospitalizations due to RSV in infants per year. Although most RSV infections of the lower 
respiratory tract are caused by RSV alone, occasionally, secondary bacterial infection further 
increases lung damage and disease severity.  Despite the widespread infections by RSV 
throughout the world, till now there are no approved vaccines or therapeutic compounds to 
treat RSV infection other than Ribavirin and prophylactic administration of Palivizumab. 
There are several animal models of RSV infection, but neonatal lambs infected with RSV 
have several advantages for modeling RSV infection in infants such as similarity in 
pulmonary architecture, immune response, and respiratory tract size, viral replication, and 
lesion development.  
To further extend the neonatal lamb model to evaluate secondary bacterial infection 
associated with RSV, lambs coinfected with RSV and Streptococcus pneumoniae were used 
to determine feasibility, susceptibility and disease development. Lambs developed severe 
disease when coinfected with both microorganisms with more severe suppurative bronchitis 
and pneumonia. Streptococcus pneumonia infection enhanced the severity of RSV in lambs 
when lambs were coinfected with both microorganisms.  
To evaluate the efficacy of some antiviral compounds, two antiviral compounds 
efficacy were tested in the neonatal lamb model of RSV infection. First, three regimens of 
xi 
 
JNJ-49214698, a small molecule RSV fusion protein inhibitor were tested (prophylactic, 
early treatment, late treatment). JNJ-49214698 prevented RSV infection when given before 
infection and reduced RSV induced lung lesion when used to treated established infection. 
Additionally, late treatment at day 3 post RSV infection had a wide window for RSV 
treatment. Secondly, 3 doses of RSV-NFI, an RSV non-fusion inhibitor were tested for 












CHAPTER 1: GENERAL INTRODUCTION  
 
Statement of the Problem 
Respiratory Syncytial Virus (RSV) is one of the leading cause of acute lower respiratory tract 
infection in infants. Each year there are about 33 million lower respiratory tract infection cases in 
children under the age of five around the world and these often lead to significant hospital 
admission and mortality[1]. Additionally, RSV is one of the leading cause of pneumonia in older 
adults and high-risk (e.g., immunosuppressed) individuals [2,3]. RSV infections can occur year 
round but peaks in the winter months [4,5].  RSV has similar hospitalization rate and disease 
burden to influenza in elderly[3]. Secondary to RSV infection, about 40% of RSV infected children 
develop co-infections with bacteria or at increased risk of secondary bacterial pneumonia [6].  
Furthermore, RSV infection in the early childhood may have delayed sequelae such as airways 
hyperreactivity, wheezing, and asthma in later childhood [7,8].  There is no vaccine or antiviral 
agent available clinically against RSV except for prophylactic humanized monoclonal antibody 
Palivizumab which has questionable efficacy and is expensive and Ribavirin [9,10]. 
There are many investigators developing new vaccines and therapeutic compounds for RSV 
and many of these are in advanced human clinical trials.  Some newly developed vaccines under 
investigation provide an acceptable level of protection against RSV [11,12].  However, formalin-
inactivated vaccines developed in the 1960’s led to enhanced disease and even death upon RSV 
infection in infants.  Therefore, there are fears of adverse side effects of any new RSV vaccination 
regimen [13]. Newly developed anti-RSV therapeutic compounds that have reached advanced 
clinical trials include those targeting several critical viral components such as RSV fusion protein, 
N protein, L protein, SH protein, and M2-1 protein, and are from four chemical classes including: 
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anti-RSV immunoglobulins, siRNA-interference, fusion inhibitors, and small molecule inhibitors 
[14,15].  These therapeutic strategies require animal models to evaluate their efficacy.  
Creating animal models for RSV investigations is challenging.  There are several animal 
models used to evaluate RSV infection, pathogenesis, and therapeutic efficacy and these include 
but are not limited to:  chimpanzees, baboons, sheep, cotton rats, mice, ferrets, and cattle [16]. Of 
these, lambs have several features advantageous as a model of RSV infection of infants including 
susceptibility to the human strains of RSV, lung development, structure and cellular morphology, 
and lesion development and lesion composition [17,18].   
Specific Aims 
The goals of the studies done in this dissertation are to determine the extent to which RSV 
infection can alter the susceptibility of the lung to Streptococcus pneumoniae (Spn), and test the 
efficacy of novel anti-RSV compounds. The hypothesis is that RSV infection enhances Spn 
infection and/or vice versa by lung damage induced by either pathogen and that anti-RSV (fusion 
and non-fusion inhibitors) can reduce RSV infection and disease severity.  This hypothesis was 
tested by: 1) a study in which lambs were infected with Spn 3 day after initial RSV infection 
(Chapter 2). 2) a study to test the efficacy of anti-RSV small molecule fusion protein inhibitor 
(Chapter 3). 3)  a study to test the efficacy of anti-RSV non-fusion inhibitor (Chapter 4).  
Dissertation Organization 
This dissertation describes the pathogenesis of secondary bacterial pneumonia in the neonatal 
lamb model of RSV infection and two therapeutic approaches to RSV infection.  The dissertation 
composed of five chapters with the 1st one as general introduction and literature review.  Chapters 
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2, 3, and 4 are composed of the three individual manuscript prepared for the peer review journal 
submission, with the final chapter (Chapter 5) as the conclusion and future direction.  
The first paper Spn infection in RSV infected neonatal lambs (Chapter 2) were submitted to 
the journal Emerging Microbes and Infection.  The second paper, Therapeutic efficacy of JNJ-
49214698, an RSV fusion inhibitor, in RSV-infected neonatal lambs, were partially published in 
the journal Nature Communications, and the full manuscript was submitted to Frontiers in 
Microbiology. The third manuscript, therapeutic efficacy of RSV-NFI in RSV infected lambs will 
be submitted to a journal publishes work on antiviral compounds at a later time.  
Literature Review 
 Respiratory Syncytial Virus Structure and Strains 
RSV is an enveloped virus with non-segmented negative-sense single-stranded RNA within 
the family of Pneumoviridae, genus Orthopneumovirus, [19,20].  The viral RNA is composed of 
10 genes that encode 11 protein two of them non-structural protein.  In general, Orthopneumovirus 
have three externally protruded glycoproteins, the attachment (G), fusion (F), and small 
hydrophobic (SH).  These glycoproteins pin the outer lipid envelope obtained from the host cell 
plasma membrane and attached to the underlining matrix (M) protein. The G protein has carboxy-
terminal located to the outside of the virion and is variable among RSV strains.  The G protein 
mediates viral attachment to cellular membrane.  The F protein has amino-terminus oriented to the 
outside of the viral envelope and is less variable between strains than the G protein and responsible 
for the viral fusion and entry into the target cell.  These two proteins are critical for the viral 
replication and infection, although virions lacking G protein can penetrate and replicate in cell 
culture, but less efficiently than virion having both G and F protein[21].  The G protein is heavily 
glycosylated and attaches to glycosaminoglycans on the host cell surface[22].  Most neutralizing 
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antibodies are directed against G protein.  Therefore, RSV has an immune evasion strategy by 
which a secreted form of G protein (sG) is produced in order to avoid inhibition by neutralizing 
antibody [23–25].  On the other hand, F protein is highly conserved, and upon attachment and 
activation, F protein undergoes conformational changes leading to fusion of the virus to the target 
cell membrane, which subsequently induce internalization of the virus into the cell cytoplasm [26–
28]. Interestingly, one study demonstrated that RSV internalized intact into the epithelial cell by 
macropinocytosis initiated by the RSV attachment.  This process leads to RSV virion to be present 
within intracytoplasmic fluid-filled macropinocytosome, then followed by F protein cleavage and 
viral fusion that leads to internalization of RSV to the cytoplasm and infection [29]. SH protein 
function and location is not fully characterized [30,31].  However, SH protein was demonstrated 
to have an antiapoptotic activity by inhibiting TNF-α signaling [32].  Another study demonstrated 
that SH protein is a small hydrophobic protein (∼100 amino acid) called Viroporin, which enhance 
infected cell permeability by forming a hydrophilic pore in the infected cell membrane [33]. The 
non-segmented single-stranded RNA associated with five structural proteins, the first 3 are 
nucleoprotein (N), large (L) protein, and phosphoprotein (P) to form the helical nucleocapsid. The 
L protein considered the RNA dependent RNA polymerase used in viral genome replication. 
Additionally, L protein responsible for the transcription of the positive sense viral mRNA, and 
possess capping enzyme activity at the 5’end and polyadenylation at the 3’ end of the viral mRNA 
[34].  N Protein forms a complex with the RSV RNA called ribonucleoprotein complex that acts 
as a template for the L protein, while P protein serves as a link between L and N protein to facilitate 
efficient and specific recognition of ribonucleoprotein complex by L protein [35].  The other two 
proteins associated with the nucleocapsid are the M2-1 and M2-2 proteins which are transcriptional 
5 
 
enhancer proteins [36]. These proteins bind to the RNA and P protein to prevent premature 
termination of transcription [37,38].   
There are two RSV strains: an A and a B strain which differ substantially in the G protein 
and noncoding portion of the genome but have less variability in the other structural 
proteins[39,40].  These two RSV strains co-circulate clinically throughout the year with the 
dominance of A strain. Furthermore, RSV group A causes more severe infection than group B 
RSV [41–44]. 
Disease Burden 
RSV is a common respiratory disease affecting all ages and especially children worldwide 
[1,45,46].  In most infected individuals, RSV causes mild to moderate upper respiratory tract 
infection characterized by fever, nasal congestion, cough and rhinorrhea that persists for several 
days [47].  However, RSV can lead to severe acute lower respiratory tract infection (LRTI) in 
infants, elderly and immunocompromised individuals [48–50]. 
All infants eventually become infected by RSV, and it is estimated that there were 33.8 
million cases of RSV associated pneumonia worldwide in children under the age of five in 2005 
[1]. Furthermore, about 3.4 million RSV associated pneumonia cases required hospital admission 
with 66,000-199,000 resulted in mortality.  Most cases of mortality occur in developing countries 
[1]. Based on US National viral surveillance data from 1990-1999, RSV associated deaths in 
infants was nine times the number of deaths related to influenza infection in the United States and 
RSV was the second leading viral cause of death after influenza in children age 1-5 years and older 
adults [51]. While the rate of RSV associated hospitalization is 30 per 1000 in the US, Japan 
reported 60 hospital admissions per 1000 [47]. RSV seasonality is consistent throughout Europe 
which accounts for 42-45% hospital admission due do LRTI [47].  In Belgium alone and during 
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2000 season, RSV was associated with 63% of acute LRTI in children under the age of 5 [52]. 
Another study in England and Wales concluded that RSV was associated with 60-80% mortality 
more than that of influenza in a total of 15 winters from January 1975 to December 1990 [53].  In 
Australia, a retrospective study of 3 RSV seasons in 1997-1999, concluded that RSV is a 
significant cause of morbidity and low mortality with 11.4% of infants required admission to 
intensive care unit [54].  In general, temperate reigns experience RSV year round with a peak in 
winter months, while a specific RSV seasons were seen in tropical regions [55]. RSV considered 
an important nosocomial agent since RSV aerosolized particles persist for an extended time in the 
urgent care clinic and can be inhaled and infect other patients [56]. However, several risk factors 
determine the severity of RSV infection in infants. 
RSV infection has considerable morbidity and mortality in infants less than 3 months and 
those having one or more risk factors [57].  There are several risk factors associated with the host 
include not limited to premature birth, congenital heart diseases, and chronic lung diseases [58,59].  
However, a high proportion of infants hospitalized due to RSV are healthy without any 
involvement of any of these risk factors [60].  Other risk factors related to the host or the 
environment are gender (males), young age (less than 6 months), number of siblings, daycare 
attendance, and exposure to tobacco smoke[61–64].  Other risk factors that can contribute to the 
severity of RSV infection are related to the virus itself.  There is a significant association between 
viral load the severity of infection [65–67].  In addition to the viral load, RSV type A is associated 
with more severe respiratory illness in compare to type B RSV [41,68,69].  Considering all the 
mentioned risk factors, RSV disease severity is an association of all these risk factors, and despite 
the massive burden of RSV disease, there are no fully satisfactory treatment or vaccine strategies 
available for RSV infection. 
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Only two therapeutic agents, Ribavirin and Palivizumab, were approved against RSV 
infection but both have limitations in efficacy. Ribavirin, a nucleoside inhibitor, developed in 1972 
as a virostatic agent for both RNA and DNA viruses[70].  Even though Ribavirin had a positive 
impact in high-risk patients such as transplant and immune compromised patients [71,72], only 
marginal clinical benefits were seen in RSV lower respiratory tract infection in general patients.  
Also, Ribavirin has a degree of toxicity.  Thus, Ribavirin is no longer recommended as anti-RSV 
treatment[73–75].  Palivizumab is a humanized monoclonal antibody against RSV F protein and 
thereby prevents/blocks virus fusion to the host cell as well as cell to cell fusion [76].  Palivizumab 
use is restricted to premature infants 32-35 weeks gestation due to high cost and is used as 
prophylactic treatment [77].  Adding to Palivizumab’s high cost, a Palivizumab-resistant variant 
of RSV have been isolated from Palivizumab treated patients [78].  Vaccination and vaccine 
development has been held back by the severe RSV infection which occurred in a 1960 vaccination 
trial in which majority of vaccinated infants had a vaccine-enhanced disease that require 
hospitalization with several fatalities [79].  Animal models for RSV infection is an essential step 
in the investigation of RSV pathogenesis and the search for new therapeutics and vaccines. 
RSV causes respiratory tract lesions that include severe bronchiolitis characterized by 
epithelial cell degeneration and necrosis with areas of hyperplasia in response to the cell damage 
along with syncytial cell formation.  The bronchiolar lumen becomes partially occluded by 
neutrophils, occasional macrophages, seroproteinaceous fluid, mucin, and cell debris.  
Lymphocytes infiltrate the airway adventitia.  The virus also infects ciliated epithelial cells of the 
upper respiratory tract and bronchi.  With time after infection, lesions can resolve. However, there 
can be increases in Goblet cells and increased residual mast cells and eosinophils.   
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Animal Models of RSV Infection 
Animal models are needed to study RSV pathogenesis and evaluate new therapeutics and 
vaccines candidates.  Animal models are considered the middle stage between tissue and cell 
culture studies in vitro and human clinical trials. However, developing animal models for RSV 
infections is very challenging due to the high degree of specificity of the hRSV to its natural host 
and lack of virulence in other species.  The specificity of hRSV is due to F protein, while lack of 
virulence in other species is due to the inability to block interferon response [80,81].  Ideal RSV 
models need to mimic several RSV disease aspects such as clinical signs and symptoms, viral 
replication, upper and lower respiratory pathology, and immune response.  Several animal models 
have been developed to address some of these aspects if not all, but each model has its strengths 
and limitations.  In general, RSV animal models are either heterologous or cognate host-virus 
models. hRSV can infect and replicate in heterologous host-virus models such as chimpanzees, 
baboons sheep, Cotton rats, ferrets and mice, while related Orthopneumovirus specific to the 
model was used in the cognate host-virus models such as murine pneumonia virus in mice model 
and bovine RSV (bRSV) in calves [16].  In this section, several animal models of RSV infection 
will be discussed concluding with the neonatal lamb model. 
Chimpanzees seem ideal as RSV animal model due to anatomical similarity to human and 
since RSV isolated originally from chimpanzees with respiratory tract infection in 1956 [82]. 
hRSV able to infect and replicate in the nasal sinuses and upper respiratory tract epithelium, and 
induce disease symptoms similar to that found in human RSV associated upper respiratory tract 
infection [83,84].  The drawback of this model is that chimpanzees rarely develop RSV LRTI.  
There are also concerns with the substantial economic, ethical and emotional burden associated 
with the use of chimpanzees.  However, vaccine studies have benefited from chimpanzees since 
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chimpanzees tend to develop anti-RSV neutralizing antibody and their immune response similar 
to that found in human [85,86].  Baboons have been used as well and are being bred in large 
numbers at Oklahoma State University for use in RSV studies and other disease conditions [87,88]. 
Although rodents are an excellent animal model for experimental studies, they are considered 
semi-permissive for hRSV replication, and need a large inoculum to induce mild to moderate RSV 
disease[89,90].  Clinical signs are difficult to interpret in rodents, and RSV induces only mild to 
moderate bronchiolitis and pneumonia[91,92]. Cotton rats are more permissive than mice for RSV 
replication and considered the standard model for testing RSV therapeutics[93]. Mice, however, 
have the advantage of wide variety of transgenetic mice and the availability of molecular markers. 
Furthermore, mice can be used as a cognate host-virus model by usingmurine pneumonia virus, 
which develop a disease in mice similar to RSV disease in human[94]. Murine pneumonia virus 
targets bronchiolar epithelium and lead to severe disease with marked respiratory disease correlate 
positively with the viral inoculum[94,95]. The drawback of murine pneumonia virus model of 
hRSV is the far phylogenetic distance between the two viruses [96]. The critical disadvantage of 
rodents as a model for RSV disease is the difference in lung anatomy, histology and immune 
response between human and rodents that subsequently question the translations of studies done 
in these models to human. 
Another cognate host-virus model for hRSV is the bRSV in calves. bRSV induce a 
respiratory disease in calves similar to what seen in human RSV.  bRSV is more closely related to 
hRSV than other non-RSV viruses and share about 38-41% homology on nucleotide level[97]. 
bRSV induces upper and lower respiratory tract infection in calves[98].  Furthermore, calves have 
similar lung anatomy and histology, i.e., the presence of pharyngeal and nasopharyngeal tonsils, 
the presence of ciliated pseudostratified epithelium and submucosal glands, and similar innate and 
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adaptive immune response to human [99,100].  The drawback of the calves bRSV model is the 
large size of calves that need special housing and handling.  Also, calves are not susceptible to 
human strains of RSV.  Thus, bRSV and hRSV are two distinct viruses that induce similar disease 
process in their natural target host.  
Neonatal lambs infected with RSV has several similarities to a human infant advantageous 
for comparison.  The most important criterion is that lambs are naturally susceptible to human, 
ovine and bovine strains of RSV. hRSV replicates mostly in the lower part of the respiratory tract 
of lamb lungs (bronchioles and bronchi) which models well bronchiolitis in infants and reduces 
airflow to alveoli. hRSV replicates well in neonatal lamb respiratory tract airways with a peak of 
viral replication at day 6 after intratracheal inoculation with A2 hRSV strain then declines with 
time[17,18]. However, another study using hRSV M37 strain showed that peak viral replication 
was at day 3 and persisted until day 6 post nebulization[101].  As in human infants, lambs have 
variable clinical signs associated with hRSV infection.  Clinical symptoms vary from mild such as 
nausea, fever, reluctant to move, and reduce milk consumption to moderate and severe such as 
cough, wheezing, expiratory efforts.  Signs of infection appear as early as 2 days post infection 
and progress till day 6 [17,101,102].  hRSV infected lambs develop lower respiratory tract 
infection characterized by moderate to severe bronchiolitis and interstitial pneumonia.  There is 
modest thickening of alveolar septae due to edema, type II cell hyperplasia and, leukocytes 
infiltration in the alveolar wall, and neutrophils and macrophages infiltration into the alveolar and 
bronchiolar lumens.  In addition, hRSV incites epithelial cell necrosis, hyperplasia of nearby 
epithelial cells and syncytial cell formation in lambs [103] as in infants. 
Additionally, immunological response to hRSV in neonatal lambs were characterized by the 
Th1 proinflammatory response as it characterized by the elevated level of IFN-γ and TNFα 
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cytokine and decrease in the level of TGF-β and IL-10.  Leukocyte recruitment to the lung were 
associated with IL-8, MCP-1, and MIP-1α increase in the lung [18].  IL-10 increased to the highest 
level in lambs lung at day 3 post-infection while other cytokine increase later in the course of the 
disease [101,104].  Lambs have many similarities to human infant that make it ideal for studying 
infant respiratory diseases.  Lung development is similar between lambs and infants in terms of 
alveolarization which occurs prenatally, similar airways size and branching (dichotomous 
branching), presence of submucosal glands, and similar percent of club cells in the airways[105–
108]. Lambs can be born preterm similar to human.  Since there is no transfer of immunoglobulin 
from ewes to their lambs in utero, lambs can be colostrum deprived to avoid transmission of 
maternal immunoglobulin to the lambs.  Finally, the size of lambs allows for better evaluation of 
the clinical signs, sampling, and lung evaluation.   
Immune Response to RSV Infection: 
Cell-mediated immune response guided by the proliferation of cytotoxic T cell is the 
preferred response to clear many viral infections, although both cell-mediated and humoral 
response needed for the ideal antiviral response. The innate immune response, however, has a huge 
effect in limiting RSV replication and respiratory infection in infants.  
The innate immune response is a nonspecific response aiming to prevent and reduce initial 
infection to allow time for more specific acquired immune responses to develop. Innate barriers in 
the respiratory tract such as mucociliary system act to prevent attachment of RSV to the airway 
epithelial cell, which is the target cell for RSV.  Additionally, in response to infection, infected or 
neighboring cell upregulate genes, and produce cytokines and antimicrobial peptides and proteins, 
which limit the microbial proliferation.  There are several common cells in the bronchoalveolar 
tree: ciliated bronchial epithelial cells, club cells, non-ciliated cells of the bronchiolar epithelium, 
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and pneumocytes (Type II and Type I).  These cells sense the presence of RSV through pattern 
recognition receptor most importantly TLR-2, TLR-4, TLR-6, TLR-7, TLR-8, Retinoic acid-
inducible gene I-liKe receptor, and MDA-5[109,110].  Activation of the TLRs eventually leads to 
the production of cytokines that shape up the immune response and attract more immune cells to 
the lung. Such cytokines include IL-8, IL-10, and IL-6 that induced by TLR4 activation, RANTES, 
which produced in response to TLR3 activation, and IFN-α, IFN-β and IP10 production in response 
to RIG-I activation[109,111–114].  IL-8, which is a neutrophils chemoattractant, is produced in 
the respiratory tract during RSV infection and higher levels of IL-8 is associated with more severe 
RSV bronchiolitis in human[115,116].  IL-10 and IL-6 are associated with the Th2 response. 
RANTES is a chemoattractant for T cells and eosinophils and associated with severe RSV 
bronchiolitis and induction of allergic cellular response [117–119]. IL-10 is an anti-inflammatory 
cytokine produced by inflammatory cells mainly macrophages and elevated during acute RSV 
infection[120,121].  IFN-α and IFN-β are type I interferons that act on reducing viral replication 
and promote MHC type I upregulation and subsequently killing of viral infected cells. Although 
IFN-α is elevated in RSV infected infants, its level is markedly lower than influenza-infected 
patients[122–124].  That is may be due to the ability of RSV to resist Interferon through the 
function of NS1 and NS2 proteins [125–127].  IFNγ, which is type II interferon, is associated with 
Th1 response, and it is produced in part by natural killer and macrophages. Low level of IFNγ is 
associated with severe RSV lower respiratory tract infection [128]. On the other hand, high level 
of type III interferon, IFN-λ, is associated with increased RSV severity.  Type III interferon has 
similar activity to type I IFN[129]. 
Mucus and fluid covering the respiratory epithelium contain other innate antimicrobial 
substances that act on deactivating microorganisms such as secretion of the submucosal glands 
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and antimicrobial peptides.  Submucosal glands, which are present in both human and ruminant 
lung airways, secrete lactoperoxidase, lactoferrin, and lysozyme into the mucosal surface. 
Lactoperoxidase acts on thiocyanate and hydrogen peroxide present on the mucosal surface to 
produce oxythiocyanate which has antimicrobial activity against bacteria and viruses[130,131]. 
Antimicrobial peptides present in the respiratory system include alpha and beta-defensins, and 
cathelicidin.  Significant antimicrobial proteins include surfactant protein A and D.  Both SP- A 
and D are produced by type II pneumocytes and club cells into the airways lumen.  Surfactant 
protein A and D are globular mannose-binding C-type lectins that bind to RSV F protein and 
enhance clearance[132–134]. A higher level of  SP-A and SP-D are associated with severe RSV 
LRTI[135]. Beta-defensins are antimicrobial peptides secreted by respiratory epithelial cells either 
constitutively such as HBD1 or inducible upon infection of the cell such as HBD2, 3, and 4. 
Inducible HBD bind to RSV envelop preventing the virus from infecting the cell[136]. Sheep 
produce Sheep beta defensins 1 and 2.  In contrast, the antimicrobial peptide Cathelicidin is 
secreted by leukocytes and stored in neutrophils and can be upregulated during viral 
infection[137].  All these innate immune responses are directed towards carbohydrate or other 
moieties rather than specific antigens and some are upregulated with RSV lower respiratory tract 
infection. In addition to the ability to deactivate RSV, some of these molecules act as a 
chemoattractant for other inflammatory and immune cells.  
Several inflammatory cells are associated with severe RSV lower respiratory tract infection. 
However, neutrophils are the predominant inflammatory cell that increased with the RSV both in 
peripheral blood and in the respiratory system [138,139], and the increased number of neutrophils 
in blood correlated with the severity of the disease and the peak of the viral load[140].  These 
neutrophils are activated and producing neutrophil elastase[141], with neutrophils apoptosis and 
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NETosis to trap virions and prevent further spread of virions[142].  In contrast, eosinophils also 
are activated during RSV infection, but they are associated with the healing process[143]. 
Eosinophils are increased following some RSV infections and contribute to asthma development 
later in life and peripheral eosinophils are increased in children hospitalized for RSV LRTI along 
with an increase in the Leukotriene C4, eosinophil-derived neurotoxin, and eosinophil cationic 
protein in the respiratory tract [85,144,145]. Other inflammatory/ innate immune response 
associated cells are macrophages, Natural killer cells, and Dendritic cells. 
Although there is a predominance of neutrophil in the airway lavage fluid obtained from 
severe RSV infected infant, changes in other cell type can be associated with the disease 
outcomes[146,147]. Alveolar macrophages have an essential role in phagocytizing foreign bodies 
and microorganisms leading to the subsequent microbial killing and antigen presentation. In 
addition to the expression of RSV glycoproteins, alveolar macrophages associated with RSV 
infection express immune modulatory molecules such as HLA-DR, interleukin-1β, and TNF as a 
response to lung injury[148,149]. RSV immunoreactive staining were seen in alveolar 
macrophages in lambs infected with hRSV[150]. Similar to macrophages, dendritic cells (DC) 
internalize proteins, process and present antigen to other immune cells, and both conventional and 
plasmacytoid DC are recruited to the respiratory system early in RSV infection. These DC are 
activated and express a proinflammatory phenotype[151–153]. Most of these cells are nonspecific 
and respond to RSV infection to either eliminate the virus or stimulate other type of immune cells 
such as lymphocytes.  
Lymphocytes are critical for RSV infection since they determine the magnitude and type of 
the acquired immune response. However, T lymphocyte number in the blood is decreased in 
patients with RSV associated LRTI, and the reduction in T lymphocytes number correlated with 
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the severity of RSV infection [138,154]. In contrast, there is an increase in the B lymphocytes 
number in circulation during severe RSV bronchiolitis [155]. Both T and B lymphocytes are 
needed to resolve RSV disease.  
During RSV infection, there is a decrease in the number of all T lymphocyte population in 
the blood, which is more pronounced in infants, and these peripheral lymphocytes are not activated 
as is shown by the low level of expression of CD11a and CTL-4 markers[138,156,157]. Although 
there is a predominance of CD4 T cell in the BALF obtained from early severe RSV infected 
infants, there is a higher expansion of effector CD8 T cell with the course of infection[146,158]. 
Most research in RSV immunobiology suggests an imbalance in Th1/Th2 response, which 
determines the severity of RSV infection.  While Th1 responses associated with cytotoxic T 
lymphocytes activation and IgG type immunoglobulin production result in resolution of RSV 
infection, Th2 shifted responses are associated with increased mucus secretion, cellular infiltration 
and atopic type reaction characterized by eosinophilia and eosinophil infiltration in the lung. Th1 
response characterized by elevation of IFN-γ, IL-1, IL-2, IL-12, IL-18, and TNF-α, while TH2 
response associated with the increase in IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13[159]. Since TH1 
and Th2 mutually inhibit each other by IFN-γ to suppress Th2 and IL-4 to inhibit Th1, INF-γ/IL-
4 ratio is used as an indicator for the Th2 bias[160]. There is lower IFN-γ and higher IL-4 leading 
to higher IFN-γ/IL-4 ratio in RSV associated bronchiolitis, in addition to the higher IL-10/IL-12 
ratio[161].  This high IFN-γ/IL-4 ratio indicates either poor Th1 response or enhanced Th2 
response. The fact that IFNγ (Th1 cytokine) level in RSV infected infants is lower than what found 
in Pneumovirus infected infants and that the IL-4 level (Th2 cytokine) is higher in RSV infected 
infants, it suggests that theTh2 response is enhanced in RSV infected infants[162]. Another study 
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in RSV infected infant indicted the predominance of the Th2 cytokines in the nasopharyngeal fluid 
[163]. Thus, Th2 enhanced response might be associated with the severe RSV bronchiolitis.  
There is an increase in B-lymphocytes in the blood of RSV lower respiratory tract infected 
infants. Humoral immune response to RSV infection includes IgM, IgA, and IgG production 
within 5-10 days post infection. However, lower immunoglobulin responses are detected in 
children under 6 months old. Both free and cell bounded anti-RSV IgA is present in the 
nasopharyngeal secretion of RSV infected patients. Anti-RSV IgG is increased in RSV infected 
patients in both IgG1 and IgG3 subclasses. Antibodies directed to F protein crossreact with 
different RSV strains, while anti-G protein antibodies are strain specific [164,165]. Although both 
anti-RSV IgG and IgA are associated with protection against RSV infection, nasal IgA is more 
protective than serum neutralizing IgG antibody[166,167]. A similar finding was seen in children 
where high IgA level seemed to be associated with recovery[168]. Another study indicated that 
lack of IgA RSV-specific memory B cells in the blood of experimentally infected adults and this 
may explain the susceptibility to recurrent infection with RSV [169]. 
Secondary Bacterial Infection 
Secondary bacterial infection is a challenging potential sequel to viral pneumonia.  There are 
few reports of bacterial infections secondary to RSV infections due to the limitation in the 
diagnosis of such infections i.e., the bacterial infection masked by the pathological changes 
induced by the virus with difficulty in obtaining noninvasive specific diagnostic samples[170]. 
Thus, there are few reports on the magnitude/extent of bacterial infection secondary to RSV 
infection.  One study indicates approximately 40% of patients hospitalized due to viral respiratory 
tract infection were associated with bacterial co-infection[171], while another study showed that 
40% of children infected with RSV have bacterial coinfection or in high risk of bacterial 
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pneumonia [6].  The most common bacteria associated with secondary bacterial pneumonia are 
Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, and Haemophilus 
influenza[172,6,173,174].  Because of a high percent of viral-bacterial coinfections, a synergistic 
relationship between the two microbial agents that leads to enhanced host susceptibility to each 
pathogen has been proposed. 
Several in vitro and in vivo models investigated the relationship between viral and bacterial 
respiratory infection and how these two microorganisms enhance virulence and persistence of both 
pathogens.  One study determined that IFN elevation induced by RSV infection enhanced 
Pseudomonas aeruginosa biofilm formation in human bronchial epithelial cell culture along with 
an increase in iron and Iron transport protein (Transferrin) secretion in the apical epithelium 
promoting P. aeruginosa biofilm both in vitro and in vivo [175].  Another study with influenza 
infected mice followed by Streptococcus pneumoniae (Spn) infected challenge revealed increases 
in both viral and bacterial titers.  It is thought that Spn leads to enhanced viral release from infected 
cells, and alveolar macrophages impairment resulting in increased Spn [176].  An In vitro study 
determined a 2-10 fold increase in the adherence of  Spn to RSV infected respiratory cell line in 
comparison to non-infected cells[177], while another study showed that 2-2.2 fold increase in 
Haemophilus influenza and Streptococcus pneumoniae attachment to cells expressing RSV G 
glycoprotein than cells infected with vector only.  Furthermore, this bacterial adherence was 
reduced to 78-84% when cells were incubated with anti-RSV G antibody [178].  In addition to 
viral-specific characteristics that enhances bacterial coinfection, the viral infection itself lead to 
alterations in host susceptibility to infection.  
There are several potential mechanisms by which viruses predispose to secondary bacterial 
infection.  The most critical factor is epithelial necrosis and damage, which give access for 
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pathogenic bacterial to its receptors and to obtain iron and other micronutrients [179]. 
Additionally, viral infection leads to disabled innate barriers such as loss of mucociliary clearance 
mechanisms leading to increased bacterial colonization and increased numbers of bacteria reaching 
deeper location within the respiratory tree[180].  Viral infection creates a microenvironment 
suitable for bacterial proliferation such as aggregation of fibrin, mucus, and necrotic cells, and the 
occlusion of small airways leading to reduced O2 and CO2 concentration[181,182].  Furthermore, 
bacterial coinfection increases viral titer and prolong the course of infection with some reports 
demonstrating that bacterial infection increases susceptibility to viral infection [180,183]. 
RSV Therapeutics  
RSV is a global burden and contributes significantly to increased hospital admission rates 
and mortality due to severe bronchiolitis and pneumonia, and there is no effective specific 
therapeutics for RSV infection.  There are only two approved treatments, Ribavirin, and 
palivizumab, although Ribavirin no longer being recommended for treatment and Palivizumab 
recommended as a prophylactic treatment only in high-risk individuals.  Additionally, 
corticosteroids and bronchodilator have limited effects and benefits.  The only therapeutic options 
available in clinical settings are supportive cares such as oxygenation and intravenous fluid[184]. 
There is an increased interest from pharmaceutical companies to develop direct antiviral 
compound suitable for treatment of RSV infection especially for infants and immunocompromised 
individuals. Several compounds that differ in their characteristics and molecular targets have been 
evaluated, and some have reach advanced clinical trials.  
Four classes of anti-RSV therapeutics been developed and investigated: immunoglobulins, 
siRNA-interference, fusion inhibitors, and small molecule inhibitors. Several types of 
Immunoglobulins have been developed and most of them targeting RSV F protein.  Both 
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polyclonal and monoclonal antibodies have been utilized as therapies with monoclonal showing 
the higher neutralizing effect and lower adverse effects. siRNA is used to interfere with RSV-
directed protein synthesis. Anti-RSV therapeutic been developed target five different RSV 
proteins[15].  
Since RSV F protein is critical for RSV entry and spread to adjacent cells, most of the anti-
RSV therapeutics target F protein. Several F protein inhibitors are either neutralizing antibody 
fragments or small molecules. Two compounds in this category (ALX-0171, REGN-2222) have 
reached advanced clinical trials (phase 3 human clinical trials). ALX-0171 is trimeric Nanobody 
(camelia antibody ) that binds the antigenic site II of RSV F protein [185], while REGN-2222 is a 
fully human monoclonal antibody[186].  Both antibodies bind to prefusion F protein preventing 
entry and multicyclic RSV infection. Other small molecules that target F protein have reached 
advanced clinical trials. These anti F protein compounds bind to F protein preventing its functional 
activity and transformation to post-fusion conformation. Since the transformation of the metastable 
pre-fusion to the 6-helix bundle post-fusion conformation is critical for RSV entry to the cell, these 
anti-F small molecule inhibitors deactivate RSV and limit the infection. Several molecules in this 
category reached advanced clinical trails such as GS-5806, JNJ-53718678, and AK0529). One 
downside for F protein inhibitor is the development of resistant viral mutation (escape mutations) 
[187].  Another RSV target is the L-protein, which is the RNA-dependent- RNA polymerase. 
Previously recommended anti-RSV compound Ribavirin is in this class. ALS-008176, a 
nucleoside analog chain terminator, is a newly developed RSV polymerase inhibitor developed by 
Alios Janssen and now in advanced clinical trials[188]. Other target proteins are N protein, SH 
protein, and M2-1 protein. Several anti-RSV molecules developed targeting these proteins, and 
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they are progressing toward clinical trails [189–191]. Another possible anti-RSV infection 
therapeutic is to target host immune response to infection.  
The severe inflammatory and cellular infiltration associated with severe RSV infection lead 
to the belief of bidirectional approach in developing anti-RSV lower respiratory tract infection 
therapeutic, i.e., specific anti-RSV molecules and immunomodulatory therapeutic such as 
chemokines and anti-leukotriene[192]. Blocking either of CCL3 (MIP-1α) or CCL5 (RANTES) in 
RSV infected animal model showed a significant reduction in the recruitment of inflammatory 
cells and increased survival[193,194]. Anti-leukotriene is also investigated since leukotriene is 
prominent during RSV bronchiolitis and showed that anti-leukotriene administration reduces 
inflammatory cellular infiltrate, reduced airway blockage, and reduced bronchiolitis in RSV 
infected mice and infants [195,196]. Other immunomodulating agents such as surfactant protein, 
vascular endothelial growth factor are also investigated and reduced RSV-associated pathology 
[197]. 
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Abstract 
Background: Respiratory syncytial virus (RSV) is the primary cause of viral bronchiolitis 
resulting in hospitalization and the most frequent cause of secondary respiratory bacterial infection 
especially by Streptococcus pneumoniae (Spn) in infants.  While murine studies have demonstrated 
enhanced morbidity during a viral/bacterial co-infection, human meta-studies have conflicting 
results.  Moreover, less is known about the pathogenesis of Spn serotype 22F and especially the 
co-pathologies between RSV and Spn dual infections.   
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Objective: The objective of this study was to determine interactions and mechanisms that 
contribute to co-pathogen-induced morbidity using a neonatal lamb model naturally permissive to 
infection by both pathogens.  
Methods: Colostrum deprived lambs (aged 3-5 days) were randomly divided into four 
groups.  Two of the groups were nebulized with RSV M37 (1.27 x 107 IFFU/mL), and the other 
two groups nebulized with cell–conditioned mock media. At day 3 post-infection, one RSV group 
(RSV/Spn) and one mock-nebulized group (Spn only) were infected with (2x106 cfu of Spn) 
intratracheally. At day 6 post-infection all lambs were humanely euthanized, and bacterial/viral 
pathogeneses were assessed by culture, viral infectious focus forming unit assay, RT-qPCR, 
immunohistochemistry, and histopathology.  
Results:  Lambs dually infected with RSV and Spn had higher RSV titers, but lower Spn 
than the other comparable groups.  Additionally, lung lesions were observed to be more intense in 
the RSV/Spn group characterized by increased interalveolar wall thickness accompanied by 
neutrophil and lymphocyte infiltration.   
Conclusions: Despite lower Spn in lungs, lambs co-infected with RSV demonstrated greater 
morbidity and tissue histopathology.  Thus, the perception of enhanced disease severity may be 
due to observed lesion development rather than elevated bacterial pathogenesis. 
 
Introduction 
Respiratory Syncytial Virus is one of the leading cause of severe lower respiratory infection 
in infants under the age of five leading to 600,000 deaths worldwide [1].  RSV is a member of the 
pneumoviridae family that infects all infants by the age of two years [2].  Although mild to 
37 
 
moderate upper respiratory tract infection is the most common form of infection, severe lower 
respiratory tract can develop leading to severe pneumonia and/or bronchiolitis that leads to 
hospitalization and sometimes death [3–5].  Lower respiratory tract infection increases the 
susceptibility to secondary bacterial infection(s) leading to severe and life-threatening pneumonia 
[6]. Streptococcus pneumoniae (Spn) is one of the most common bacterial infections that occurs 
concurrently with respiratory viruses such as influenza and RSV [7].   
Spn is a Gram-positive facultative anaerobic bacterial pathogen that causes invasive disease 
including sepsis, meningitis, and pneumonia. Similar to RSV, Spn cause severe illness and presents 
with higher incidence in both children and the elderly worldwide [8].  Pneumococcal pneumonia 
is one of the leading causes of bacterial pneumonia in children worldwide, responsible for about 
11% of all deaths in children under the age of five (700,000-1 million every year).  Most of these 
deaths occur in developing countries [9].  Spn vaccines are effective in reducing the incidence of 
pneumonia caused by the serotypes contained in the vaccine [10].  However, the emergence of 
non-vaccine serotypes and persistence of antibiotic-resistant Spn such as serotype 19A highlights 
the importance of more investigation into Spn pathogenesis and therapy.  Since Spn has an essential 
role in secondary bacterial infections following viral pneumonia or viral-bacterial co-infection 
[7,11], animal modeling for the purpose of understanding viral-bacterial co-infections are crucial 
to investigating therapeutics that combat both.  Moreover, most studies have concentrated on 
influenza and Spn co-infections but mainly in murine models with few mechanistic studies done 
in humans other than calculation of frequencies of co-infections with these two pathogens.  Despite 
the importance of RSV/Spn co-infections, far fewer studies have been done in this area as 
compared to influenza/Spn. Furthermore, less is known about emergent serotype 22F pathogenesis 
[12,13].  We have extensively used a neonatal lamb model to mimic RSV lower respiratory tract 
38 
 
infection in infants as a preclinical model to evaluate the efficacy of new therapeutics [14,15] and 
to understand RSV pathogenesis [16–18].  Sheep are also permissive to Spn infection and have 
served as a model of Spn sepsis that appears to manifest clinical signs similar to human infection 
[19,20].  Thus, in the present study, we investigated a co-infection of neonatal lambs using 
RSV/Spn as an alternative large animal model to better understand viral/bacterial co-infections in 
the young with the objective of gaining more insight into serotype 22F pathogenesis in the lung. 
Material and Methods 
Experimental Design 
Animals:  A total of 20, 2-3 day-old, colostrum-deprived lambs, were randomly divided into 
four groups with 5 animals per group: RSV only, RSV-Spn co-infection, Spn only, and uninfected 
control. Animal use was approved by the Institutional Animal Care and Use Committee of Iowa 
State University. Two groups were nebulized with RSV M37 (1.27x107 IFFU/mL) on day 0. One 
of the RSV infected groups was injected intratracheally with 2 ml normal saline as a mock Spn 
infection (RSV group), while the second RSV-infected group was injected intratracheally with 2 
ml solution containing Spn serotype 22F (2x106 CFU/ml) 3 days post-RSV nebulization (RSV-
Spn group). The other two groups were nebulized with cell-conditioned mock media containing 
20% sucrose at day 0 and injected intratracheally with either normal saline (control group) or 
solution containing Spn (2x106 CFU/ml) at day 3 post nebulization (Spn group). At day 6 post-
RSV infection, all lambs were humanely euthanized. Autopsy was performed to evaluate the 
macroscopic lung lesions. Lung samples were collected including sterile lung tissue for bacterial 
isolation, frozen lung sample for RT-qPCR, bronchioalveolar lavage fluid (BALF) from right 
caudal lung lobe for RSV infectious focus forming unit (IFFU) assay and RT-qPCR, and lung 
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pieces from different lobes were fixed in 10% neutral buffered formalin for histological 
assessment.  
Infectious Agents 
Lambs were infected with RSV strain M37, purchased from Meridian BioSciences 
(Memphis, TN, USA). This strain is a wild type A RSV isolated from the respiratory secretions of 
an infant hospitalized for bronchiolitis [21,22]. M37 was grown in HELA cells and stored at -80°C 
in media containing 20% sucrose [23]. 6 mL of 1.27 x 107 IFFU/mL in media containing 20% 
sucrose or cell-conditioned mock media (also containing 20% sucrose) was nebulized using PARI 
LC Sprint™ nebulizers to each lamb over the course of 25-30 minutes resulting in the total 
inhalation of about 3 mL by each lamb [23]. Spn serotype 22F was grown overnight at 37°C in 
Todd Hewitt media containing 2% yeast extract, 50 g/ml of gentamicin, and 10% bovine serum. 
Colony forming units (CFUs) were calculated by OD600 with confirmation by dilution plating on 
Tryptic Soy Agar (TSA) plates with 5% sheep blood containing gentamicin. 
Lung RSV viral and Spn bacterial titers 
BALF collected from right caudal lobe at necropsy  was used to evaluate RSV IFFU. BALF 
were spun for 5 minutes at 3,000g to pellet large debris. Supernatants were then spun through 0.45 
am Costar SPIN-X filters (microcentrifuge 15,600g) for 5 minutes. The resulting BALF samples 
were applied to HELA cells grown to 70% confluence in 12-well culture plates (Fisher Scientific, 
Hanover Park, IL) at full strength, and three serial dilutions (1:10, 1:100, and 1:1000); all samples 
were tested in triplicate to determine the viral titer.  Lung tissue samples were used to determine 
Spn titer. Lung tissue samples were  placed in 500 μl of sterile PBS and were mechanically 
homogenized. Lung homogenates were pelleted at 100x g, for 5 minutes. Supernatants were 




Formalin-fixed paraffin-embedded tissue sections were used for IHC which was performed 
according  to a previously published protocol in our laboratory [18,24]. Briefly, after 
deparaffinization and rehydration, antigen retrieval was performed in 10mM TRIZMA base (pH 
9.0), 1mM EDTA buffer, and 0.05% Tween 20 with boiling under pressure for up to 15 minutes. 
Polyclonal goat anti-RSV antibody (Millipore/Chemicon, Temecula, CA; Cat. No. AB1128) was 
used as the primary antibody after two blocking steps. The first blocking was with 3% bovine 
serum albumin in Tris-buffered saline+0.05% Tween 20 (TBS-T) and the second was 20% normal 
swine serum in TBS-T for 15 minutes each. Primary antibody was followed by application of 
biotinylated rabbit anti-goat secondary antibody (KP&L; Cat. No. 16-13-06). Signal development 
was accomplished using a 1:200 dilution of streptavidin-horseradish peroxidase (Invitrogen; Cat. 
No. 43-4323) for 30 minutes followed by incubation with Nova Red chromagen solution (Vector; 
Cat. No. SK-4800). Positive signal was quantified in both bronchioles and alveoli for each tissue 
section, and a score of 0-4 was assigned according to an integer-based scale of:  0=no positive 
alveoli/bronchioles, 1=1-10 positive alveoli/bronchioles, 2=11-39 positive alveoli/bronchioles, 
3=40-99 positive alveoli/bronchioles, 4=>100 positive alveoli/bronchioles. IHC for Spn was 
performed using rabbit anti-Streptococcus pneumoniae polyclonal antibody (Thermo Fisher 
scientific cat. # PA-7259) followed by biotin-labeled goat anti-rabbit IgG antibody (Thermo Fisher 
Scientific Cat.#: 65-6140). Five random images were taken for each tissue section that were then 
analyzed by the quantitative Halo program.  
Quantitative Reverse Transcription Polymerase Chain Reaction (RT-qPCR) 
BALF and lung tissue homogenates in Trizol were used to assess RSV mRNA expression by RT-
qPCR. The assay was performed as published previously in our laboratory [18,24,25].  Briefly, 
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RNA isolation from lung tissue and BALF was performed using the TRIzol method followed by 
standard DNase treatment. RT-qPCR was carried out using One-Step Fast qRT-PCR Kit master 
mix (Quanta, BioScience, Gaithersburg, MD) in a StepOnePlus™ qPCR machine (Applied 
Biosystems, Carlsbad, CA) in conjunction with PREXCEL-Q assay-optimizing calculations. 
Primers and probe for RSV M37 nucleoprotein were designed based on RSV accession number 
M74568. Forward primer: 5′-GCTCTTAGCAAAGTCAAGTTGAACGA; reverse primer: 5′-
TGCTCCGTTGGATGGTGTATT; hydrolysis probe: 5′-6FAM-
ACACTCAACAAAGATCAACTTCTGTCATCCAGC-TAMRA. 
Hematoxylin-Eosin Staining and Histological Scoring of Lung Sections 
hematoxylin-eosin stained sections were examined via light microscope. An integer-based score 
of 0-4 was assigned for each parameter (bronchiolitis, syncytial cells, epithelial necrosis, epithelial 
hyperplasia, alveolar septal thickening, neutrophils in bronchial lumen, neutrophils in alveolar 
lumen, alveolar macrophages, peribronchial lymphocytic infiltration, perivascular lymphocytic 
infiltration, lymphocytes in alveolar septa, fibrosis), with 4 as the highest score. A final score was 
calculated by adding up all measured scores to form a 0-48 score, with 48 as the highest, which is 
called the accumulative histopathological lesion score.  
 
Statistical Analysis 
 Statistical analysis used the Wilcoxon signed-rank test for non-parametric parameters such as 
accumulative microscopic lesion scoring, followed by nonparametric comparisons for each pair 
also using the Wilcoxon method. One-way ANOVA was followed by all pairs comparison by the 





Infected Lambs Showed Marked RSV and Spn Titer 
RSV titers and Spn colony-forming units were measured in this study to evaluate the degree 
of infection by each pathogen and to investigate the possible effect(s) of co-infection in the 
combined RSV-Spn group on the replication of each infectious agent. As measured by IFFU, 
infectious RSV was detected in both RSV and RSV-Spn groups (P<0.0001) (Figure 1a). RSV titer 
trended (not significant) 0.15 fold higher in the RSV-Spn group than RSV alone. A similar trend 
was observed when assessing RSV mRNA detected in BALF by RT-qPCR. RSV mRNA was 
elevated in both RSV and RSV-Spn groups (7.28 and 7.31 virion/ml) (Figure 1b). Furthermore, 
similar to the viable virus titer increase, RSV virions measured by RT-qPCR in the lung of the 
RSV-Spn group were 0.6 fold higher than the RSV-only group (Figure 1c). In contrast, Spn was 
isolated in the lung tissue of both the Spn only and the RSV-Spn groups (56902.75 and 5456 
CFU/ g, respectively) (p<0.0001) (Figure 1d). In contrast to the RSV/Spn group, the bacterial 
titer was 9.4 fold higher in the Spn only infected group (p<0.05) (Figure 1d). Interestingly, Spn 
titers in lambs that died before the end of the study were the highest of their groups. Lamb number 
22 that was found dead 36hr after Spn infection in the RSV-Spn group had 59,302 CFU/ g, while 
lamb number 9 that was euthanized 48 hr after Spn infection in the Spn group had a titer of 
9,302,325 CFU/ g (Figure 1d).  Spn was detected in the blood in both Spn infected groups - 
indicating bacteremia/sepsis (Figure 1e). 
RSV and Spn Induce a Well-recognized Macroscopic and Microscopic Lesion 
Percent of lung tissue with gross lesions related to either infectious agent was determined at 
necropsy coupled with post-necropsy retrospective qualitative analyses. Both RSV and Spn-related 
lesions were found scattered across the lung surface in all lung lobes.  Pinpoint dark red areas of 
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lung consolidation characterized RSV lesions. These areas were obvious in RSV and RSV-Spn 
groups (P<0.001, and p<0.005, respectively). There were no significant differences in the 
percentage of lung RSV macroscopic lesions detected between RSV and RSV-Spn groups (Figure 
2a).  Spn gross lesions are characterized by larger sizes of lung consolidation with bright red color 
- which was seen to a lesser extent when compared to RSV lesions (Figure 2b). When combining 
lesions observed associated with both RSV and Spn, there was a significant increase in observed 
lesions within both RSV-infected groups in comparison to the Spn only group (p<0.001) (Figure 
2c). 
Microscopic lesions observed within the lung tissue reflected the infectious agent used and 
contradicted our initial expectations (i.e. microscopic lesions caused by RSV infection were 
multifocal areas of interstitial pneumonia and bronchiolitis scattered randomly and 
homogeneously throughout the lung tissue). However, Spn induced diffuse homogenous and subtle 
pathological changes in the lung tissue. Infection with either Spn, RSV, or both, markedly increase 
microscopic lesions (accumulative microscopic lesion score) associated with the disease in 
comparison to the control group (p<0.05) (Figure 3a-f). Additionally, the combined RSV-Spn 
infection significantly increased the severity of microscopic lesions in comparison to the Spn only 
group (p<0.05). Lesions varied among lambs, and RSV lesions consisted of thickening of the 
interalveolar wall with inflammatory cellular infiltrates in the airway adventitia and lamina propria 
(lymphocytes and plasma cells), alveolar lumen (alveolar macrophages and neutrophils), and 
bronchiolar lumen (neutrophils). With RSV, overall, there was a varied degree of epithelial 
necrosis and syncytial cell formation. On the other hand, Spn lesions consisted of moderate 
interalveolar wall thickening with inflammatory cellular infiltrate mainly in the alveolar septae. 
Most of the microscopic lesions seen with RSV overlapped with Spn-induced injury. However, 
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congestion of the interalveolar wall capillaries and hemorrhage was seen only in Spn-infected 
lambs.  
Immunohistochemistry was used to identify and localize RSV and Spn in tissue sections. 
RSV were present multifocally throughout the sections with bronchial and peribronchial 
distribution (Figure 4c). Therefore, RSV expression was evaluated in bronchioles and alveoli 
separately. There were marked increases in RSV expression in bronchioles in both RSV only and 
RSV-Spn groups (p<0.005 and p<0.001, respectively) with high RSV expression in the alveoli of 
the RSV-Spn group (p<0.01) (Figure 4a).  There were no significant differences between the RSV 
only and RSV-Spn groups in the degree of RSV expression in lung tissue sections. Spn was random 
and homogenously scattered throughout the lung sections with more intense signal in interalveolar 
walls and blood capillaries (Figure 4d). Although not significant, there was a 0.5 fold increase in 
Spn in the Spn only group when compared with the RSV-Spn group (Figure 4b).  
Discussion 
There is a critical need for an animal model to study bacterial pneumonia secondary to an 
initial viral infection in the lung in order to study the mechanisms of viral-bacterial co-infection 
and to evaluate therapeutic interventions.  There are significant advantages of using lambs to model 
RSV infection as a correlate for human infants - including the ability to use human viral strains 
without adaptation and the similarity of the pathological sequelae [16,17].  In this study, we 
demonstrate that Spn readily infects the lungs of lambs and establishes active bacterial pneumonia.  
A previous study revealed that the peak of RSV titer and infection in lambs is around day 3 post-
viral nebulization, and we used this time-frame to model early human co-infection [24].  The 
results of this study demonstrate consistency in the infection rate of both RSV and Spn, as well as 
a good relation to the lesion development induced by either of the infectious agents.  Although we 
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used 2 x 106 CFU of Spn  for infection, murine studies typically use 5x105 to 107 CFU to establish 
productive infections.  Moreover, the lung volume of lambs is significantly larger than mice which 
suggests that our inoculating dose may be more dispersed throughout the lungs than murine 
studies.  We believe that we may also be able to reduce the infection dosage to a lower CFU or 
potentially use a colonization model to examine co-infection and pneumonia development.  
The RSV titer in our study was increased by 0.5 fold in the RSV-Spn group, but bacterial 
presence was reduced by 9.4 fold when compared to  the RSV and Spn groups, respectively.  These 
data are consistent with prior studies in mice with influenza/Spn co-infections demonstrating 
higher viral loads [11,26], although our observed viral (RSV) increase was quite modest in 
comparison.  Influenza co-infection studies also predict higher Spn burdens in the lungs due to 
damaged epithelial cells serving as anchor points for the opportunistic bacteria. In other studies, 
RSV with Spn in mice or cell culture predict that the RSV G protein on the infected epithelial 
surface could also serve as an anchor point for Spn in the lungs [27]. In contrast to these murine 
models, we found lower bacterial loads in the co-infection group over the Spn only group.  These 
findings suggest that the immune response might control Spn in the lungs of lambs better than 
mice.   Importantly, in human clinical studies of co-infection, show in increase in nasal 
colonization numbers of Spn upon viral infection but this does not translate into higher invasive 
lung disease [28]; suggesting that higher bacterial burdens could be a murine artifact rather than a 
mechanism enhancing disease.  In human studies of high Spn colonization, RSV disease appeared 
less severe [29] suggesting that further using the lamb model to explore mechanistic differences 
between Spn colonization and pneumonia during RSV. 
The only deaths that occurred in the present study were in the Spn-infected groups, and both 
lambs (lamb 11 in the Spn only group, and lamb 23 in the RSV-Spn group) had high lung Spn 
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colony-forming units/gram tissue. These could represent a failure to control bacterial division and 
subsequent septicemia. 
Lesion severity was consistent with the RSV titer and Spn burden as is shown by the 
significant increase in the percent of lung tissue involved by gross lesions, and the increase in the 
evaluated histological parameters.  Gross lesions were multifocal lesions scattered randomly in all 
lung lobes - which is the typical lesion distribution induced by RSV nebulization [18,24]. 
However, presentation of Spn gross lesions contradicted what was expected by the apparent 
development of lesions in all lobes - including the caudal lung lobe, which is not typical for 
bacterial pneumonia in lambs.  However, the diffuse bacterial lesions and the presence of Spn 
lesions in the caudal lobe may be due to the inoculation technique used for Spn infection.  For Spn 
infection, lambs were held vertically by one person and injected intratracheally by the second 
person leading to a fall of inoculum through the bronchial tree into the caudal lobe, which in this 
case, was favorable since it gives a bronchopneumonic distribution similar to that found in humans. 
It is also possible that Spn spreads across lung lobes after inoculation either by airflow or vascular 
flow.  RSV-induced microscopic lesions were more prominent in comparison to Spn-induced 
lesions and subsequently lead to significant differences between the RSV-Spn and Spn only 
groups’ accumulative histologic lesion scores.  RSV was more prominent in the bronchioles, while 
Spn was diffuse throughout the lung sections.  
Although mechanisms are being assessed, the higher observed morbidity in the RSV/Spn 
group may derive from an enhanced neutrophil response present in the lungs.  Evidence for this is 
supported by the histopathology and the lower Spn burdens in these animals.  Likely, RSV 
infection served as a first activating response to neutrophils that could have then better controlled 
the secondary bacterial infection.  It is also possible that alveolar macrophages were activated by 
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RSV that, in turn, secreted inflammatory mediators that enhance neutrophil activation. Enhanced 
neutrophil/leukocyte activation contrasts with studies in influenza co-infections in mice – which 
suggests innate immune exhaustion [30]. While the time of inoculation could be a reason for the 
observed differences, another could be the mere difference between influenza and RSV 
pathogenesis. In either case, the results suggest further avenues of study using this model. We are 
currently evaluating the neutrophil responses in these animals to ascertain how the innate antiviral 
response may have played a role in better limiting the bacterial infection. The observed higher 
RSV infection rate in the co-infection could also derive from the greater number of neutrophils in 
the lungs in this group. There is evidence that RSV can infect neutrophils in humans [31] including 
our unpublished data. Thus, if dual infection with Spn leads to enhanced neutrophil recruitment to 
the lungs over RSV alone, those cells could become infected and contribute to the higher viral titer 
we observed in the dual infection group. The effects of RSV infection on neutrophilic antibacterial 
responses would be an interesting further study.  
In this study, we have developed an animal model of co-infection for RSV and Spn.  We 
have determined enhanced disease with co-infection of both pathogens that correlates with human 
and murine influenza studies, but this may all be due to a complex enhanced inflammatory/immune 
response to co-infection rather than direct damage by either pathogen alone, although we cannot 
rule the culpability of co-infection causation out.  Future studies will plan to utilize other serotypes 
of Spn to determine whether the results we observed are unique to serotype 22F or whether they 
are a trend for all Spn strains in general.  Additional studies will allow refinement of this model 
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Figure 2-1:RSV and Spn titer in lung tissue and blood 
(a) number of infectious RSV particles as measured by IFFU assay, (b) RSV mRNA level in the 
BALF, (c) RSV mRNA level in lung tissue (d) Spn colony forming unit per 100 μg lung tissue, (e) 
Spn colony forming unit per 100 μl blood, all shown as average + SEM. Animals were either 
infected with mock media (control), RSV, Spn, or RSV followed by Spn (RSV-Spn). *P<0.05, 

































Percent of lung tissue associated with RSV lesions (a), Spn (b), and both RSV and Spn (c); with 
photographic representative of each.  All show average and SEM. Lambs were either infected with 
mock media (control), RSV, Spn, or RSV followed by Spn (RSV-Spn). *P<0.05, **P<0.01, 






































































































(a) accumulative histologic lesion associated with RSV and Spn infection shown as average + 
SEM. (b-f) show a representative photograph of lung tissue sections stained with Gram 
stain (b), H&E stained tissue section of control (c), RSV only (d), Spn only (e), combined 
RSV-Spn (f). Lambs were either infected with mock media (control), RSV, Spn, or RSV 
































































Number of bronchioles and alveoli express the RSV positive signal (a), surface area (mm2) 
occupied by Spn IHC positive staining (b), all shown as average + SEM.  (c) and (d) show a photo 
representation of RSV (c) and Spn (d) IHC positive staining. Animals were either infected with 
mock media (control), RSV, Spn, or RSV followed by Spn (RSV-Spn). * P<0.05, **P<0.01, 
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Figure 2-4:Immunohistochemistry staining of RSV and Spn in FFPE lung tissue sections. 
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Respiratory syncytial virus (RSV) is a leading cause of respiratory infection, hospitalization, 
and death in infants worldwide. No fully effective RSV therapy using direct antivirals is marketed. 
Since clinical efficacy data from naturally infected patients for such antivirals are not available 
yet, studies in animals are indispensable to predict if therapeutic intervention. Here we report the 
impact of an RSV fusion inhibitor, JNJ-49214698, on severe RSV-associated acute lower 
respiratory tract infection (ALRTI) in neonatal lambs. Randomized animals were treated once-
daily with 25 mg/kg JNJ-49214698, starting either before RSV infection, 1 day post-infection, or 
as late as peak lung viral load on Day 3 post-infection. The efficacy of treatment was assessed by 
scoring clinical signs of illness, development of RSV-induced gross and microscopic lung lesions, 
and measuring virus titers in the lungs. Treatment with JNJ-49214698 was very effective in all 
treatment groups. Even in animals for which treatment was delayed until peak viral load was 
reached, a reduced amount and severity of gross and microscopic lesions as well as RSV titers and 
RNA levels were found. These results strongly suggest that treatment with small-molecule fusion 
inhibitors is an effective strategy to treat patients who are diagnosed with an RSV-induced ALRTI. 
Key Words 
Respiratory Syncytial Virus, small molecule fusion inhibitor, RSV Fusion inhibitor, 
antiviral, neonatal lamb model, acute lower respiratory tract infection 
 
Introduction 
Respiratory syncytial virus (RSV) is one of the leading causes of acute lower 
respiratory tract infection (ALRTI). Globally, it is estimated that 33.8 million cases of 
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ALRTI associated with RSV infection occur yearly in children under the age of five. 
Subsequently, RSV-associated ALRTI is a major cause of hospital admissions with an 
estimated 3.4 million cases annually; and RSV-associated mortality is estimated to be 
66,000-199,000 in children under the age of five occurring mostly in developing countries 
[1]. Furthermore, post-bronchiolitic development of wheezing syndrome is sometimes 
observed, and although still under debate, it was suggested that the development of asthma 
could be associated with RSV infection [2,3]. RSV is also one of the leading causes of 
respiratory infection in the elderly and high risk adults [4,5]. A recent study showed that 3% 
of pneumonia cases in human adults is caused by RSV [6] and with the widespread use of 
influenza vaccination, RSV has a similar disease burden in the elderly [4]. 
Despite decades of investigation, no market-approved vaccine exists [7]. Seasonal 
prophylaxis with the monoclonal antibody palivizumab, restricted to high-risk infants in 
developed countries, is the only specific antiviral strategy available [8]. The disease 
preventive effects of palivizumab in these patients were demonstrated by a significant 
reduction in hospitalization rate, hospital residence time, admission to intensive care unit and 
days requiring oxygen therapy [9]. However, the therapeutic efficacy of antibodies like 
palivizumab in infants hospitalized with an established RSV-associated ALRTI is 
questionable at best [10–12]. Other drugs like bronchodilators, corticosteroids, and 
antibiotics, often used but not indicated to treat RSV-associated bronchiolitis, do not seem 
to confer sufficient therapeutic benefit either, leaving supportive care essentially as the major 
treatment option [13,14]. 
New treatments are clearly needed to decrease the medical consequences related to 
RSV-associated ALRTI. Data on the impact of small-molecule direct antivirals on RSV 
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disease manifestation in naturally infected hospitalized patients or outpatients are not 
available, and as such, reliable modeling of human RSV disease remains a necessary step in 
the search for novel therapies. 
The development of an RSV experimental human infection model has provided a new 
tool to obtain human proof-of-concept efficacy data of RSV direct antivirals early in the 
clinical development pipeline [15–17]. However, volunteers are often young, healthy adults 
and infection is studied only in the upper respiratory tract, limiting the information about the 
efficacy of therapeutics to treat ALRTI. Therefore, the recent development of a fully-
replicative neonatal lamb model for RSV has presented a significant step forward to generate 
reliable preclinical efficacy data and to improve the selection of the proper clinical candidate 
molecules. Neonatal lambs are susceptible to human as well as ovine and bovine strains. 
Similarities between the pulmonary and immunological systems between lambs and humans 
make the neonatal lambs an excellent model to study human RSV disease and the impact of 
new potential RSV therapeutics[18,19]. Moreover, neonatal lambs infected with RSV 
develop clinical symptoms including but not limited to fever, tachypnea or increased 
expiratory effort (wheeze), lethargy, and develop mild to moderate bronchiolitis and 
pneumonia. Innate and adaptive immune responses by neonatal lambs are very similar to 
those of human infants [20,21]. 
A promising approach to inhibit RSV is by targeting the viral fusion (F) protein [22,23]. 
A few small-molecule RSV fusion inhibitors are currently being evaluated in early-stage 
clinical trials, but their clinical impact on RSV-associated ALRTI in hospitalized infants is 
yet unknown [24–26]. The purpose of this study is therefore to evaluate the therapeutic 
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impact of an experimental RSV fusion inhibitor, JNJ-49214698, on RSV-associated ALRTI 
using a lamb model of RSV infection. 
Materials and Methods 
 (see online Supplementary Data for detailed methods) 
Compound and Dosing 
JNJ-49214698 was discovered and synthesized by Janssen Infectious Diseases (Beerse, 
Belgium). The compound was formulated in 10% acidified hydroxypropyl-β-cyclodextrin 
[10% HP-β-CD + HCl, pH 2 (vehicle)] at 6.25 mg/mL prior to dosing and stored throughout 
the study at 4 °C. The compound was dosed orally by catheter-mediated orogastric gavage 
at  4 mL/kg body weight (25 mg/kg) once daily. Dose selection in this study aimed for 
reaching the highest possible, safe exposure in the animals in order to maximize the 
likelihood to obtain efficacy while avoiding toxic side effects. A daily oral dose of 25 mg/kg 
was selected based on the antiviral activity of JNJ-49214698 [EC50 = 0.4 ng/mL (0.8 nM) 
and EC90 = 2.4 ng/mL (4.8 nM)], JNJ-49214698 exposure levels obtained in neonatal lambs 
at different doses during a separate pharmacokinetic (PK) study and an observed lack of 
toxicity of JNJ-49214698 at least until Cmax = 17,167 ng/mL and AUC0-24h = 139,993 
ng.h/mL in a 5-day repeated dose rat tolerance study. 
Animals 
Twenty-one colostrum-deprived neonatal lambs (Suffolk, Polypay, Dorsett cross) aged 
1-3 days and 2-7 kg body weights were obtained for this experiment. Animal use was 
approved by the Institutional Animal Care and Use Committee of Iowa State University. 
RSV-infected lambs were kept in a separate room from the non-infected animals in the 
Livestock Infectious Disease Isolation Facility (LIDIF). Lambs were fed iodide-free lamb 
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milk replacer diet (Milk Products Inc., Chilton, WI, USA) [27], and were treated with Naxcel 
(Ceftiofur sodium, Pfizer) intramuscular once daily to reduce/prevent secondary bacterial 
infections.  
Experimental Design 
Lambs were randomly assigned to five different groups. Three groups (Px, Tx-1 and 
Tx-2) were infected with RSV and treated with JNJ-49214698. The first group (Px, n = 4) 
was treated prophylactically, 1 day before RSV challenge and then daily afterward up until 
Day 5 post infection (p.i.). The second (Tx-1, n = 5) and the third (Tx-2, n = 5) groups were 
treated one day and three days after viral challenge and daily afterward up until Day 5 p.i., 
respectively. The vehicle group (n = 4), serving as a positive RSV control group, was infected 
with RSV, but received treatment with vehicle only. The No RSV group (n = 3), served as 
negative RSV control group, and was aerosolized with RSV-free, HEp-2 cell-conditioned 
media and also received vehicle. All lambs were euthanized at Day 6 p.i. and all endpoints 
measured after euthanasia. 
RSV Infection 
Lambs were infected with RSV strain M37, purchased from Meridian BioSciences 
(Memphis, TN, USA). This strain is a wild type A RSV isolated from the respiratory 
secretions of an infant hospitalized for bronchiolitis [28,29]. In our laboratory, M37 was 
grown in HEp-2 cells and stored at -80°C in media containing 20% sucrose [30]. Six mL of 
1.27 x 107 Infectious Forming Unit (IFFU)/mL in media containing 20% sucrose or cell-
conditioned mock media (also containing 20% sucrose) was nebulized using PARI LC 
Sprint™ nebulizers to each lamb over the course of 25-30 minutes resulting in the total 




JNJ-49214698 exposure in plasma, BALF, and lung homogenate samples was assessed 
using a method based on Protein precipitation and HPLC/MS/MS analysis. Quantitative 
reverse transcription polymerase chain reaction (qRT-PCR) was done to measure the RSV 
mRNA expression in BALF and lung homogenate samples as previously done in our lab 
[30,32,33]. Infectious focus-forming unit (IFFU) assay was used to determine the viable RSV 
in BALF samples as previously described [32]. Chlincal score was calculated by the number 
of respiratory associated signs present in each animal.  For the pathological study, percent of 
lung parenchyma involved with RSV induced lesion were measured to evaluate the RSV 
gross lesion. Histologically, Hematoxylin-eosin stained sections were examined via light 
microscope as described previously [32] with some modification. Lung lesions were scored 
according to an integer-based score of 0-4 for each parameter (bronchiolitis, syncytial cells, 
epithelial necrosis, epithelial hyperplasia, peribronchial lymphocytic infiltration, 
perivascular lymphocytic infiltration, neutrophils), with 4 as the highest score. Then a final 
score (accumulative histo lesion score) was assigned by adding up the scores from the seven 
individual parameters resulting in final accumulative scores ranging from 0-28 representing 
the total RSV-associated lesion in each tissue section. For further evaluation of the JNJ-
49214698 therapeutic efficacy, Immunohistochemical staining was performed to evaluate 
RSV antigen expression in lung tissue section as previously described in our laboratory 
[32,34,35]. Formalin-fixed paraffin-embedded tissue sections were used for the RNAscope 
detection of RSV mRNA in situ. A probe designed to the hRSV M37 nucleoprotein gene 
(accession number KM360090) was used (Probe-V-RSV-NP, Advance Cell Diagnostic, 
Catalog number 439866). The assay was performed according to the manufacturer’s manual 
(user manual document number 320497; RNAscope® 2.0 HD Detection Kit (BROWN) User 
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Manual PART 2). Sections were examined under light microscope, and the number of 
bronchioles and alveoli containing the positive signal were counted. The number of positive 
bronchioles and alveoli per tissue section was then assigned a score according to the simple 
integer-based scale of 0 = no positive alveoli/bronchioles, 1 = 1-10 positive 
alveoli/bronchioles, 2 = 11-39 positive alveoli/bronchioles, 3 = 40-99 positive 
alveoli/bronchioles, 4 = >100 positive alveoli/bronchioles. 
Statistical Analysis 
Statistical analysis was completed by using the Kruskall-Wallis test for non-parametric 
parameters such as accumulative microscopic lesion scoring, immunohistochemistry and 
RNAscope integer-based scores, followed by Dunn’s post-hoc test for multiple comparisons. 
One-way ANOVA followed by Dunnett multiple comparisons test was used to compare the 
treated groups to the RSV-infected non-treated control group for gross lesion scores and viral 
titer analyses by qRT-PCR. 
Results 
JNJ-49214698 Efficiently Distributes to Different Lung Compartments of Neonatal 
Lambs 
During a multicyclic RSV infection, small-molecule fusion inhibitors are thought to 
inhibit each new infection event at the time of viral fusion. The concentration of JNJ-
49214698 was measured in BALF as well as in homogenized lavaged-lung tissue. To assess 
the potential of JNJ-49214698 to distribute from the blood to the lungs of the neonatal lambs, 
we also measured its level in plasma. JNJ-49214698 was absorbed very quickly into the 
circulation and tended to slightly accumulate over time during the study period. The average 
steady-state concentration of JNJ-49214698 in plasma was in the range of 1770 ± 435 and 
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3112 ± 1441 ng/mL across the different treatment groups and was reached within 24-48 hr 
after the first dose (Figure 1a). Twenty-four hour after the final dose, the level of JNJ-
49214698 in the BALF of the group receiving prophylactic treatment (Px), or groups in 
which compound administration was started one (Tx-1) or three (Tx-2) days after viral 
inoculation was 2044 ± 648, 3289 ± 977 and 1109 ± 252 ng/mL, respectively (Figure 1b). 
The average lavaged-lung concentrations measured were 2867 ± 403, 5211 ± 841 and 1976 
± 175, in Px, Tx-1, and Tx-2 treatment groups, respectively, resulting in an approximate 
lung/plasma ratio of 1.4 to 1.8 and a good distribution of JNJ-49214698 in the BALF (Figure 
1c). Together, these results indicate a good distribution of JNJ-49214698 to different lung 
compartments. 
Treatment with JNJ-49214698 Reduces Incidence and Duration of RSV-Associated 
Symptoms 
Clinical signs of RSV infection in lambs, as in human infants, can be variable and 
sometimes difficult to assess.  Despite this, RSV-associated respiratory distress can be 
observed in the animals as early as one day p.i., developing further in some animals into clear 
external signs of RSV-associated illness such as nasal discharge, wheezing or lethargy. By 
Day 1 p.i., most of the lambs in this study, except for the animals in the non-infected group, 
had already become lethargic as characterized by decreased activity (lower frequency of 
getting up and movement in general). The behavior and respiratory-related symptoms in 
lambs of the vehicle-treated group (RSV and no treatment) steadily worsened during the 
following days (Figure 2a).  One lamb started to produce nasal discharge and displayed 
episodes of wheezing as from Day 3 p.i. onwards, while its respiratory rate was clearly 
increased by Day 6. One lamb on Day 3 p.i. died and was found during post-mortem analysis 
with severe gross lesions consistent with RSV infection in its lungs.  The other lambs 
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survived until Day 6 when they were euthanized, but by Day 4, all 4 remaining animals from 
this group were lethargic.  
In contrast, while by Day3 post-infection 3 lambs in the Px group showed fever, the 
remaining lambs in Px and Tx-1 groups were free of symptoms by Day 3 post-infection 
(Figure 2b and c). Although less prominently, the incidence and duration of RSV-associated 
symptoms was also reduced in the lambs of the Tx-2 group as compared to the vehicle-only 
treated animals (Figure 2d). 
In summary, these findings suggest that treatment with JNJ-49214698 has the potential 
to reduce the incidence and duration of the clinical manifestation of RSV disease in lambs. 
Treatment with JNJ-49214698 Inhibits a Multicyclic RSV Infection in Neonatal Lambs 
The presence of nucleoprotein RNA in BALF and lung samples was quantified by qRT-
PCR. In BALF, The Px group showed a significant 3.4 log10 (p<0.0001) reduction of the 
viral RNA level in comparison to the RSV-infected vehicle group (Figure 3a), while the viral 
RNA in the Tx-1 and Tx-2 groups was reduced less by approximately 7- and a 3-fold as 
compared to the vehicle only treated animals. We could not detect viral RNA in the lung 
tissue of prophylactically treated animals, and profound reductions in RSV RNA of 
approximately 23-fold in Tx-1 group (p<0.02), and 10-fold in Tx-2 in compared to the 
vehicle group (Figure 3b). The infectious viral titer in BALF were done and partially reported 
in a separate manuscript [23] in which IFFU were significantly reduced in all treated groups 
with no infective virus detected in Px group that receive prophylaxis with JNJ-49214698 
similar to what we found in RSV mRNA in lung tissue. There were 34- and a 93-log 
reduction in the infectious titer as compared to the RSV-infected control group, was observed 
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in the Tx-1 and Tx-2 groups, respectively (p<0.001) (Figure 3c). To confirm the quantified 
viral titers in BALF and lavaged-lung tissue, we determined RSV (M37) antigen and RNA 
by immunohistochemical and RNAscope analysis, respectively. RSV antigen was present in 
infected airway epithelial cells of bronchi, bronchioles, and alveoli and occasionally in 
alveolar macrophages. However, staining of RSV antigen was markedly reduced in all drug-
treated groups in comparison to the RSV-infected control group (Figure 4a, c). RSV antigen 
was highly decreased in the Tx-2 group as compared to the vehicle-treated group, and again, 
almost no RSV antigen was detected in both Px (p<0.01) and Tx-1 (p<0.05) treatment groups 
(Figure 4a, c). When RSV RNA (M37 nucleoprotein) expression in lungs was determined by 
RNAscope, concomitant with the RNA levels as determined by qRT-PCR, there was a 
marked reduction of RSV RNA expression in all the compound-treated groups in both 
bronchioles and alveoli (Figure 4b, d). Heavy brown staining of RSV RNA in RSV-infected 
non-treated lung sections was observed which was concentrated in the bronchioles and 
alveoli in the consolidated part of the lung (Figure 4d). In contrast, only minimal staining 
was seen in the Px (p<0.05) and Tx-1 groups (Figure 4d), aligning with 
immunohistochemical and qRT-PCR data. 
Treatment with JNJ-49214698 Inhibits RSV-Induced Lung Pathology and Cellular 
Immune Response of Neonatal Lambs 
Approximately 43% of the lung surface of infected vehicle-treated animals had RSV 
associated macroscopic lesions which were multifocal dark red pinpoint foci of consolidation 
scattered randomly over the lung surface and deeply throughout the lung tissue (Figure 5a, 
b). Moreover, gross lung lesions were evenly distributed over the different left and right lung 
lobes. Prophylaxis (Px) or treatment starting twenty-four hours after infection (Tx-1) 
completely abolished the formation of RSV associated gross lung lesion (Figure 5a, b). When 
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treatment was delayed even as late as three days after infection (Tx-2), a significant reduction 
in the RSV associated gross lesions was observed; dropping from 43 to 16% (p<0.0001) 
(Figure 5b). As a negative control, no lesions were observed in the lungs of non-infected, 
vehicle-treated animals (Figure 5b). 
To investigate the effect of JNJ-49214698 on lung tissue microscopically, we assessed 
the impact of the compound on the development of bronchiolitis, syncytial cell formation, 
epithelial necrosis and hyperplasia, and inflammatory cell infiltration in lungs. An 
accumulative histological lesion score was assigned by combining all the assessed 
parameters. Significant reductions of the accumulative score were seen across 
prophylactically treated animals or animals that received early treatment starting 1 day p.i. 
with JNJ-49214698, (p<0.01 and p<0.05, respectively) (Figure 6a). Prophylaxis with JNJ-
49214698 completely prevented the formation of microscopic lung lesions after RSV 
infection (Figure 6a, b). Although the effect on the accumulative histologic score was least 
prominent in animals that received treatment with JNJ-49214698 as late as 3 days after 
infection, a prominent reduction as compared to the vehicle-treated group was still observed, 
with some animals displaying almost no microscopic lesions at all.  
Typical RSV lesions that were present in the RSV-infected control group were 
multifocal interstitial pneumonia and bronchiolitis. There was thickening of the inter-
alveolar wall due to type II pneumocyte hyperplasia and lymphocyte infiltration (Figure 6b). 
There was neutrophil infiltration in the bronchial and bronchiolar lumens and the alveolar 
lumen with multifocal and segmental areas of necrosis and sloughing of the epithelial cells 
lining bronchioles. Some bronchioles had modest thickening of epithelium due to 
hyperplasia. In addition, there were occasional multinucleated syncytial cells present 
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throughout the lung sections. In the lesions formed in the latter Tx-1 group, the formation of 
syncytial cells, epithelial necrosis or hyperplasia and infiltrating neutrophils was absent, 
while the other parameters assessed were markedly reduced, resulting in a  prominent 
decrease of the accumulative histological lesion scores. 
Discussion 
Currently, there are no effective direct antivirals available for the treatment of RSV-
associated ALRTI.  Even though a number of RSV inhibitors have reached early-stage 
clinical evaluation, no data are available yet demonstrating their clinical benefit in naturally 
infected patients suffering from severe RSV-associated ALRTI, and so uncertainty remains 
about the therapeutic treatment window and the impact of such molecules on severe RSV 
disease.  Attempting to minimize the risk for intended late-stage clinical development, we 
therefore evaluated an experimental small-molecule RSV fusion inhibitor, JNJ-49214698, in 
neonatal lambs, a fully-replicative animal model of RSV infection closely mimicking infant 
RSV disease. 
The three treatment regimens chosen in the study all reflect realistic potential clinical 
drug administration regimens.  The first group (Px) began to receive JNJ-49214698 one day 
before viral nebulization to test the pre-exposure prophylactic effect of the compound, while 
the Day 1 p.i. treatment group (Tx-1) was used to test the effect of very early post-exposure 
treatment of an established infection. Previous RSV viral kinetic studies in our laboratory 
demonstrated that RSV replication in neonatal lambs is highest between viral inoculation and 
Day 3 p.i., reaching peak viral titer at Day 3, while RSV-associated lung pathology peaks at 
Day 6 p.i. [32]. Therefore, the Day 3 post viral challenge treatment group (Tx-2) was used 
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to test the effect of JNJ-49214698 on RSV-associated ALRTI when treatment is started close 
to peak viral titer, essentially the time patients seek first-line medical assistance and on 
average 1 day before they present to hospital [36–40].   
The overall assessments demonstrate a strong pre-exposure protective effect of JNJ-
49214698 against RSV infection. The prophylaxis (Px) group showed no gross/microscopic 
lung lesions and no viral antigen by IHC. In addition, viral RNA levels significantly reduced 
close to undetectable levels and were mirrored by no detectable IFFU[23]. Only very 
occasional infection of individual lung cells, as demonstrated by the presence of viral RNA 
(by RNAscope) in these cells was observed, consistent with earlier studies which showed 
that fusion inhibitors are effective in inhibiting syncytia formation by preventing 
transmission of the virus via cell-cell spreading [38,39]. Our data are also consistent with the 
prophylactic efficacy of Synagis®, a humanized monoclonal antibody inhibiting the fusion 
protein of RSV [8]. In contrast to Synagis®, which lacks therapeutic efficacy[8], early (Tx-
1) and late (Tx-2) therapeutic administration regimens with JNJ-49214698 displayed 
unambiguous evidence of efficacy in the neonatal lambs. Administration of JNJ-49214698 
after the establishment of a multi-cyclic ALRTI strongly reduced the severity of the infection 
as evidenced by the strong and statistically significant reduction of gross and microscopic 
changes in the lung, and decreased infectious titer in BALF as compared to vehicle-only 
animals [23]. Consistent with these results, a considerable reduction of the viral RNA 
expression in lung tissue was measured. However, the significant reduction of infectious 
virus in BALF of therapeutically treated animals was not mirrored by a reduction of the viral 
RNA to the same extent. This seeming discrepancy between viral RNA expression and 
infectious viral titer in the BALF may be explained by the ability of JNJ-49214698 to bind 
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tightly to prefusion RSV F present on the envelope of the virus, resulting in neutralization of 
the infectivity of virus particles present in the airways [22]. Although early administration of 
JNJ-49214698, starting one day after RSV infection resulted in better reduction and clearing 
of RSV infection as compared to the group that received late treatment starting at peak viral 
load, the efficacy results obtained in the latter group were clearly noticeable. 
Together, the results of this study demonstrate that pre-exposure prophylaxis and 
treatment of an established RSV infection with a small-molecule RSV fusion inhibitor results 
in significant reduction of viral replication as well as improvement of RSV-associated lung 
pathology. Moreover, our data suggest a favorable window within which to treat RSV 
infections in a community or hospital setting and contribute to the de-risking of late-stage 
clinical compound development pathways. 
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 a) shows the daily plasma concentration (ng/mL) 24 hr after the first dose and daily just before the next 
dose (Ctrough) to the end of the study. The compound reached a steady state concentration in the plasma 
within 24 h of treatment and maintained that level throughout the study. b), c) show JNJ-49214698 exposure 
in BALF (b) and lavaged lung (c) at necropsy (day 6 p.i.). 
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Figure 3-1:Exposure of JNJ-49214698 in different body compartments of neonatal lambs. 
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Figure 3-2: Clinical signs score in different groups. 
Data shown as average number of RSV-associated clinical signs observed in each group 
(wheeze, increased respiratory rate and expiratory effort). Animals were infected with RSV 
and received either vehicle only (Vehicle) and animal not infected with RSV (a), prophylaxis 
(Px) (b) or therapeutic treatment with JNJ-49214698, starting one (Tx-1) (c) or three (Tx-2) 











a) the viral RNA titer as measured by qRT-PCR in BALF, and b) the viral RNA titer as 
measured by qRT-PCR in lung tissue, c) number of infectious particles as measured by IFFU 
assay [23] with modification, all shown as average + SEM. Animals were infected with RSV 
and received either vehicle only (Vehicle), prophylaxis (Px) or therapeutic treatment with 
JNJ-49214698, starting one (Tx-1) or three (Tx-2) days post infection. Non-infected, vehicle-
treated animals were indicated as No RSV. JNJ-49214698 reduces the viable viral particles 
in BALF, as well as RSV RNA in both BALF and lung tissue. Statistical analysis was 
performed by one-way ANOVA, followed by Dunnett’s post-hoc test for multiple 
comparison correction. *p-value < 0.02; **p-value < 0.002; ***p-value < 0.001; ****p-
value < 0.0001. LLOD = lower limit of detection. 
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a) integer-based scoring of M37 antigen in lung tissue detected by immunohistochemistry, 
b) integer-based scoring of M37 RNA in lung tissue detected by RNAscope. Scoring on y-
axis represents the number of bronchioles or alveoli stained positive for M37 antigen (a) or 
RNA (b) Bars represent the average score per group + SEM. Animals were infected with 
RSV and received either vehicle only (Vehicle), prophylaxis (Px) or therapeutic treatment 
with JNJ-49214689, starting one (Tx-1) or three (Tx-2) days post-infection. Non-infected, 
vehicle-treated animals were indicated as No RSV. c) and d) show representative images of 
M37 antigen (c) and M37 RNA (d) in the lung tissue of animals allocated to the different 
treatment groups. JNJ-49214698 reduced the RSV M37 antigen and RNA in the lung of all 
JNJ-49214698-treated animals. Statistical analysis was performed by Kruskall-Wallis non-
parametric test, followed by Dunn’s post-hoc test for multiple comparison correction. p-
value bars are representative for both bronchioles and alveoli. *p-value < 0.05; **p-value < 
0.01. 
 




































































a) shows the average + SEM % of lung surface affected by RSV-induced gross lesions in the 
different treatment groups. Animals were infected with RSV M37 and received either vehicle 
only (Vehicle), prophylaxis (Px) or therapeutic treatment with JNJ-49214689, starting one 
(Tx-1) or three (Tx-2) days post infection. Non-infected, vehicle-treated animals were 
indicated as No RSV. JNJ-49214698 significantly reduces the RSV gross lesions in the 
treated groups in comparison to the vehicle group. Statistical analysis was performed by one-
way ANOVA, followed by Dunnett’s post-hoc test for multiple comparison correction. 
****p-value < 0.0001. b) shows representative images of lungs from an animal infected with 
RSV receiving vehicle only, prophylaxis with JNJ-49214698, or therapeutic treatment, 
starting one (Tx-1) or three (Tx-2) days post-infection and Non-infected, vehicle-treated 
animals were indicated as Baseline. Yellow arrows indicate variably sized dark red 
consolidated areas on the lung surface. 
 


























































a) shows the average + SEM of the accumulative RSV-induced microscopic lesions in the different 
treatment groups. Animals were infected with RSV M37 and received either vehicle only 
(Vehicle), prophylaxis (Px) or therapeutic treatment with JNJ-49214689, starting one (Tx-1) or 
three (Tx-2) days post infection. Non-infected, vehicle only-treated animals were indicated as No 
RSV. JNJ-49214698 reduces the pathological changes associated with RSV infection. Statistical 
analysis was performed by Kruskall-Wallis non-parametric test, followed by Dunn’s post-hoc test 
for multiple comparison correction. *p-value < 0.05; **p-value < 0.01. b) shows representative 














































Materials and Methods 
Compound and Dosing 
JNJ-49214698 was discovered and synthesized by Janssen Infectious Diseases (Beerse, 
Belgium). The compound was formulated in 10% acidified hydroxypropyl-β-cyclodextrin 
[10% HP-β-CD + HCl, pH 2 (vehicle)] at 6.25 mg/mL prior to dosing and stored throughout 
the study at 4°C. The compound was dosed orally by catheter-mediated orogastric gavage at  
4 mL/kg body weight (25 mg/kg) once daily. Dose selection in this study aimed for reaching 
the highest possible, safe exposure in the animals in order to maximize the likelihood to 
obtain efficacy while avoiding toxic side effects. A daily oral dose of 25 mg/kg was selected 
based on the antiviral activity of JNJ-49214698 [EC50 = 0.4 ng/mL (0.8 nM) and EC90 = 2.4 
ng/mL (4.8 nM)], JNJ-49214698 exposure levels obtained in neonatal lambs at different 
doses during a separate pharmacokinetic (PK) study and an observed lack of toxicity of JNJ-
49214698 at least until Cmax = 17,167 ng/mL and AUC0-24h = 139,993 ng.h/mL in a 5-day 
repeated dose rat tolerance study. 
Animals 
Twenty-one colostrum-deprived neonatal lambs (Suffolk, Polypay, Dorsett cross) aged 
1-3 days and 2-7 kg body weights were obtained for this experiment. Animal use was 
approved by the Institutional Animal Care and Use Committee of Iowa State University. 
RSV-infected lambs were kept in a separate room from the non-infected animals in the 
Livestock Infectious Disease Isolation Facility (LIDIF). These rooms have separate 
ventilation units as well as separate entrances and exits to avoid any cross-contamination 
between infected and non-infected lambs. Lambs were fed iodide-free lamb milk replacer 
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diet (Milk Products Inc., Chilton, WI, USA) [1], and were treated with Naxcel (Ceftiofur 
sodium, Pfizer) intramuscular once daily to reduce/prevent secondary bacterial infections.  
Experimental Design 
Lambs were randomly assigned to five different groups. Three groups (Px, Tx-1 and 
Tx-2) were infected with RSV and treated with JNJ-49214698. The first group (Px, n = 4) 
was treated prophylactically, 1 day before RSV challenge and then daily afterward up until 
Day 5 post infection (p.i.). The second (Tx-1, n = 5) and the third (Tx-2, n = 5) groups were 
treated one day and three days after viral challenge and daily afterward up until Day 5 p.i., 
respectively. The vehicle group (n = 4), serving as a positive RSV control group, was infected 
with RSV, but received treatment with vehicle only. The No RSV group (n = 3), served as 
negative RSV control group, and was aerosolized with RSV-free, HEp-2 cell-conditioned 
media and also received vehicle. All lambs were euthanized at Day 6 p.i. and all endpoints 
measured after euthanasia. 
RSV Infection 
Lambs were infected with RSV strain M37, purchased from Meridian BioSciences 
(Memphis, TN, USA). This strain is a wild type A RSV isolated from the respiratory 
secretions of an infant hospitalized for bronchiolitis [2,3]. In our laboratory, M37 was grown 
in HEp-2 cells and stored at -80°C in media containing 20% sucrose [4]. PARI LC Sprint™ 
nebulizers were used to administer virus or cell-conditioned control media (lacking RSV) to 
each lamb [5]. Six mL of 1.27 x 107 Infectious Forming Unit (IFFU)/mL in media containing 
20% sucrose or cell-conditioned mock media (also containing 20% sucrose) was nebulized 
to each lamb over the course of 25-30 minutes resulting in the total inhalation of about 3 mL 
by each lamb. 
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Animal Monitoring for Appearance of Clinical Signs and the Clinical Score 
Animals were monitored for clinical signs in the beginning of the study right before 
viral inoculation (Day 0: all animals scored 0) and immediately after each administration of 
vehicle or test article throughout the course of the study. In addition to the monitoring of 
their behavior, respiratory associated clinical signs (respiratory rate, wheezing, expiratory 
effort) were measured. Because clinical signs are variable in lambs and difficult to score in 
terms of severity, an accumulative clinical score to summarize the overall distress per group 
was applied by adding up the number of the scored clinical sings observed in each of the 
individual lambs and then averaging the daily obtained sums for the respective groups to 
normalize for group size.  
Blood sampling for PK Analysis 
Blood samples (1.5 - 2 mL) were collected from the jugular vein pre-dose (just before 
the first dose) and at 24 h following each dose until 144 h for PK analyses.  Blood was 
dispensed into 3 mL blood collection tubes containing K2EDTA anticoagulant. Blood 
samples were kept at room temperature prior to centrifugation. The blood samples were then 
centrifuged at 1,600 x g for 10 min at 4°C to obtain the plasma. Plasma was stored in 2 mL 
cryovials at -80°C. 
Lung Collection and Processing 
The thorax was opened, lungs removed and gross lesions were scored as performed 
previously (40). The lungs were also photographed in situ and ex vivo. After removal, 
percentage parenchymal involvement was scored for each lung lobe before the 
bronchoalveolar lavage fluid (BALF) collection procedure. Left and right lungs were then 
separated and each lobe excised. Tissue samples were collected from each lung lobe of all 
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animals. In brief, one sample from each lobe not destined for BALF collection (i.e. 4 lobes - 
Right Cranial, Left Cranial, Left Middle and Left Caudal) were snap-frozen in liquid nitrogen 
for qRT-PCR. Two samples from each of these lobes were placed in tissue cassettes and put 
in 10% neutral-buffered formalin (NBF) for histological and immunohistochemical analysis. 
Representative lung samples from each of these lobes were also placed into a cryovial and 
immediately snap-frozen in liquid nitrogen, then transferred to -80°C for storage and shipped 
on dry ice pellets for PK analysis of JNJ-53718678 compound at Janssen. 
BALF Collection 
BALF samples from each animal were collected immediately after euthanasia on Day 
6 p.i. from right middle and right caudal lobes as performed previously in our laboratory [6]. 
Briefly, the excised lung lobes were instilled with 5 mL of cold DMIM (42.5% Iscove's 
modified Dulbecco's medium, 7.5% glycerol, 1% heat-inactivated FBS, 49% DMEM, and 5 
μg/ml kanamycin sulfate). 100 μL of the right caudal lobe BALF was added to 1 mL TRIzol 
(Invitrogen) and kept in – 80 C for the qRT-PCR assay to assess RSV mRNA, and the rest 
of BALF sample was  placed on ice and used within 2 h for infectious focus-forming unit 
(IFFU) assay to assess the infectious RSV titer. The right middle lobe BALF sample placed 
-80°C for storage and shipped on dry ice pellets for determination of JNJ-49214698 and 





Quantification of JNJ-49214698 Exposure 
 Samples of plasma (50 µL), lung homogenate (50 µL) and BALF (50 µL) were analyzed for 
JNJ-49214698 using a method based on protein precipitation and HPLC/MS/MS analysis.  To each 
sample, DMSO (50 µL) and acetonitrile (500 µL) was added.  Samples were mixed thoroughly 
(mechanical shaking for 10 min), and then centrifuged (5000  g for 10 min at 15C).  An aliquot 
(400 µL) of the resulting supernatant was transferred to a 96-well plate and assayed for JNJ-
49214698 concentrations using HPLC/MS/MS employing positive-ion electrospray ionization 
(Sciex API 4000) and a Waters ACQUITY UPLC C18 1.7um (50 x 2.1 mm i.d.) column.  Elution 
was achieved at a flow rate of 0.8 mL/min with a gradient of 0.1% FA and acetonitrile.  The lower 
limit of quantification was 1 ng/mL for plasma, 50 ng/g for lung and 1 ng/mL for BALF.  The 
assay was linear up to 20,000 ng/mL for plasma, 5,000 ng/mL for BALF and 100,000 ng/g for 
lung. Samples of plasma and BALF were also analyzed for concentrations of urea in order to 
calculate the dilution of BALF on sample collection.  To a separate sample of plasma and BALF 
(50 µL), 50 µL H2O/acetonitrile (50/50), 50 µL internal standard, 200 µl acetonitrile was added.  
Samples were mixed thoroughly (mechanical shaking for 10 min), and then centrifuged (5000  g 
for 10 min at 15C).  An aliquot (200 µL) of the supernatant was transferred to a 96-well plate and 
evaporated at 40C with nitrogen.  An aliquot (200 µL) of camphanic chloride (1 mg/mL in 
acetonitrile) was added for derivatization. Samples were mixed thoroughly (mechanical shaking 
for 10 min) and incubated for 90 min at 37C.  After incubation, 100 µL H2O was added and assayed 
for urea concentrations using HPLC/MS/MS employing positive-ion electrospray ionization 
(Sciex API 4000) and a Waters ACQUITY UPLC HSS T3 (50 x 2.1 mm i.d.) column.  Elution 
was achieved at a flow rate of 1 mL/min with a gradient of 0.01M Ammonium formate (pH = 3) 
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and acetonitrile.  The lower limit of quantification was 2 µg/mL for plasma and BALF.  The assay 
was linear up to 10,000 µg/mL. 
Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) 
Tissue samples from right and left cranial, left middle and left caudal lung lobes (0.3–
0.4 g of each lobe) were homogenized in TRIzol (Invitrogen, Carlsbad , CA) for total RNA 
isolation according to manufacturer’s instructions and as previously described [4,6,7]. 
Briefly, RNA isolation was followed by DNase treatment (Ambion, TURBO DNase, Austin, 
TX) at 1:10 dilution in combination with RNaseOUT (Invitrogen) and nuclease-free water 
(GIBCO/Life Technologies, Carlsbad , CA). Spectrometry (Beckman Scientific, 
Indianapolis, IN) was used to assess each RNA sample isolate at a dilution of 1:50 to measure 
sample purity and quantity (A260nm/A280nm all >1.95). Agilent Bioanalyzer 2100 analyses 
of the RNA isolates gave RNA Integrity Number values > 8.0. qRT-PCR was carried out 
using One-Step Fast qRT-PCR Kit master mix (Quanta, BioScience, Gaithersburg, MD) in 
a StepOnePlus™ qPCR machine (Applied Biosystems, Carlsbad, CA) in conjunction with 
PREXCEL-Q assay-optimizing calculations [8,9]. Primers and probe for RSV M37 
nucleoprotein were designed based on RSV accession number M74568. Forward primer: 5′-
GCTCTTAGCAAAGTCAAGTTGAACGA; reverse primer: 5′-
TGCTCCGTTGGATGGTGTATT; hydrolysis probe: 5′-6FAM-
ACACTCAACAAAGATCAACTTCTGTCATCCAGC-TAMRA. Each 1:10-diluted total 
RNA sample was further diluted so that each final qRT-PCR contained 0.784 ng total 
RNA/µL; as determined to be optimal by PREXCEL-Q [10]. Thermocycling conditions were 
5 minutes at 50°C; 30 seconds at 95°C; and 45 cycles of 3 seconds at 95°C and 30 seconds 
at 60°C. Samples and standards were assessed in duplicate and each qRT-PCR quantification 
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cycle (Cq) was converted to a relative initial quantity (Xo) based on a standard curve using 
the following equation: Xo =  EAMP
(b-Cq), where  EAMP and b are the PCR exponential 
amplification efficiency value and the y-intercept, respectively, from a sample mixture 
derived standard curve for RSV M37 nucleoprotein mRNA. The efficiency-corrected delta 
Cq (EAMP
ΔCq) method was used for qRT-PCR quantification calculations. Results were 
normalized to total tissue RNA loaded per reaction (identical for all reactions). No-RT 
control reactions proved negative for RSV M37. qRT-PCR was demonstrably free of 
inhibition based on preliminary dilution threshold analyses as per the PREXCEL-Q method 
for qPCR [10,11]. 
Hematoxylin-Eosin Staining and Histological Scoring of Lung Sections 
Hematoxylin-eosin stained sections were examined via light microscope as described 
previously [6] with some modification. Lung lesions were scored according to an integer-
based score of 0-4 for each parameter (bronchiolitis, syncytial cells, epithelial necrosis, 
epithelial hyperplasia, peribronchial lymphocytic infiltration, perivascular lymphocytic 
infiltration, neutrophils), with 4 as the highest score. Then a final score (accumulative histo 
lesion score) was assigned by adding up the scores from the seven individual parameters 
resulting in final accumulative scores ranging from 0-28 representing the total RSV-
associated lesion in each tissue section. The scale used to assess the pathological changes 
briefly, for bronchiolitis scale: 0 = no remarkable lesions, 1 = minimal detectable lesion 
(epithelial degeneration in one or a few bronchioles per 20 X field), 2 = epithelial 
degeneration involving less than 10% of the airway lumen; minimal neutrophils and cell 
debris; adventitial lymphocytes in multiple bronchioles, 3 = epithelial degeneration involving 
more than 10-50% of the airway lumen with cell debris and neutrophils; adventitial 
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lymphocytes; multiple bronchioles, 4 = circumferential bronchiolitis with dense adventitial 
lymphocytes; multiple bronchioles. For syncytial cells scale: 0 = none, 1 = one distinct 
syncytial cell, 2 = up to three in three 20x fields, 3 = more than three in three fields, 4 = 
numerous. Epithelial necrosis and epithelial hyperplasia scale:  0 = none, 1 = minimally 
detectable in one or a few bronchioles per 20x per field, 2 = 10% of the bronchioles in 
multiple airways per field, 3 = 10-50% of the bronchioles in multiple airways per field, 4 = 
circumferential in multiple airways. Neutrophils scale (in bronchi, bronchioles or alveoli): 0 
= none, 1 = minimally detectable, 2 = 10 or less neutrophils in one or a few airways/alveoli, 
3 = 10 or more neutrophils in several airways/alveoli, 4 = 10 or more involving many or most 
airways/alveoli. The same scale was used for peribronchiolar lymphocytic infiltrates and 
perivascular lymphocytic infiltrates: 0 = none, 1 = earliest detectable lymphocytic infiltration 
in the adventitia, 2 = segmental to circumferential infiltration, 3 = circumferential infiltrates 
that expand more than three cells wide, 4 = circumferential infiltrates that form nodules. 
Immunohistochemistry (IHC) of Lung Sections 
IHC for determining the distribution of RSV antigen was performed as described 
previously [6,12,13]. Briefly, after deparaffinization and rehydration of the formalin fixed 
paraffin-embedded tissue sections, antigen retrieval was performed by placing the slides with 
tissue sections in pH 9.0 10mM TRIZMA base, 1mM EDTA buffer and 0.05% Tween 20 
and boiling under pressure for up to 15 minutes. Polyclonal goat anti-RSV antibody 
(Millipore/Chemicon, Temecula, CA; Cat. No. AB1128) was used as the primary antibody 
after two blocking steps, the first with 3% bovine serum albumin in Tris-buffered saline + 
0.05% Tween 20 (TBS-T) and the second with 20% normal swine serum in TBS-T, 15 
minutes each. Primary antibody was followed by biotinylated rabbit anti-goat secondary 
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antibody (KP&L; Cat. No. 16-13-06). Signal development was done by using 1:200 dilution 
of streptavidin-horseradish peroxidase (Invitrogen; Cat. No. 43-4323) for 30 minutes 
followed by incubation with Nova Red chromagen solution (Vector; Cat. No. SK-4800). The 
positive signal was quantified in both bronchioles and alveoli for each tissue section, and a 
score of 0-4 was assigned according to an integer-based scale of 0 = no positive 
alveoli/bronchioles, 1 = 1-10 positive alveoli/bronchioles, 2 = 11-39 positive 
alveoli/bronchioles, 3 = 40-99 positive alveoli/bronchioles, 4 = >100 positive 
alveoli/bronchioles. 
RNAscope 
Formalin fixed paraffin embedded (FFPE) IHC tissue sections were used for the 
RNAscope detection of RSV mRNA in situ. A probe designed to the hRSV M37 
nucleoprotein gene was used (Probe-V-RSV-NP, Advance Cell Diagnostic, Catalog number 
439866). This probe was designed to target the 8-1111 base region of the nucleoprotein gene 
of accession number KM360090.1 CDS sequence (1114-2289). The assay was performed 
according to the manufacturer’s manual (user manual document number 320497; 
RNAscope® 2.0 HD Detection Kit (BROWN) User Manual PART 2). Sections were 
examined under light microscope, and the number of bronchioles and alveoli containing the 
positive signal were counted. The number of positive bronchioles and alveoli per tissue 
section was then assigned a score according to the simple integer-based scale of 0 = no 
positive alveoli/bronchioles, 1 = 1-10 positive alveoli/bronchioles, 2 = 11-39 positive 




Infectious Focus-Forming Unit (IFFU) Assay 
Viral titers in BALF from the right caudal lobe were determined by IFFU assay [6]. 
BALF samples were spun down for 5 minutes in a centrifuge at 3,000 x g to pellet large 
debris. Approximately 800–850 μL of each supernatant was collected and then spun through 
850 μL-capacity 0.45 μm Costar SPIN-X filter (microcentrifuge 15,600 x g) for 5 minutes. 
The resulting clear BALF samples were applied to HEp-2 cells grown to 70% confluence in 
12-well culture plates (Fisher Scientific, Hanover Park, IL) at full strength and three serial 
dilutions (1:10, 1:100,and 1:1000), all tested in triplicate. The BALF samples in the wells 
were diluted with DMEM media (Mediatech, Inc., Manassas, VA) supplemented with 10% 
with heat-inactivated fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA) and 50 
μg/mL kanamycin sulfate (Invitrogen/Life Technologies). Plates were incubated for 1 hr at 
37°C, 5% CO2, then 1 mL of media was added to each well and plates were returned to the 
incubator. After a 48 hr incubation, wells were fixed with cold 60% acetone/40% methanol 
solution for 1 minute. Wells were then rehydrated with TBS-T, then blocked with 3% BSA 
solution for 15 minutes followed by overnight incubation with primary polyclonal goat anti-
RSV (all antigens) antibody (EMD Millipore Corporation, Billerica, MA, USA). The next 
day, plates were washed with TBS-T then incubated for 1 hr with secondary antibody (Alexa 
Fluor® 488 F(ab’)2 fragment of rabbit anti-goat IgG (H+L) (Molecular Probes/Life 
Technologies). Plates were rinsed and examined under inverted fluorescence microscopy 
using the FITX/GFP filter (Olympus CKX41, Center Valley, PA), and total number of IFFUs 
(which is defined here as 3 or more fluorescing cells) were counted for each well. IFFU/mL 
calculations were obtained by multiplying the average number resulting from triplicate well 
counts by the initial BALF sample dilution factor and multiplying that value by 5 to obtain 




Statistical analysis was completed by using the Kruskall-Wallis test for non-parametric 
parameters such as accumulative microscopic lesion scoring, immunohistochemistry and 
RNAscope integer-based scores, followed by Dunn’s post-hoc test for multiple comparisons. 
One-way ANOVA followed by Dunnett multiple comparisons test was used to compare the 
treated groups to the RSV-infected non-treated control group for gross lesion scores and viral 
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W = wheeze, L = lethargy, R = increased respiratory rate, Ee = expiratory effort, D = Dead, 





















Panels show the average + SEM of integer-based scoring of the lung microscopic criteria 
induced by RSV infection. Animals were infected with RSV and received either vehicle only 
(Vehicle), prophylaxis (Px) or therapeutic treatment with JNJ-49214689, starting one (Tx-1) 
or three (Tx-2) days post infection. Non-infected, vehicle-treated animals were indicated as 
No RSV. Assessed criteria were a) bronchiolitis, b) syncytial cell formation, c) epithelial 
necrosis, and d) neutrophils. (see supplementary data for Figure 8, which shows epithelial 
hyperplasia, peribronchiolar nodules, and perivascular nodules. JNJ-49214698 greatly reduces 
all assessed criteria in all treated lambs in comparison to the RSV-infected vehicle-treated lambs. 
Statistical analysis was performed by Kruskall-Wallis non-parametric test, followed by 
Dunn’s post-hoc test for multiple comparison correction. *p-value < 0.05; **p-value < 0.01; 
***p-value < 0.001. 


























































































































Panels show the average + SEM of integer-based scoring of the lung microscopic criteria 
induced by RSV infection. Animals were infected with RSV and received either vehicle only 
(Vehicle), prophylaxis (Px) or therapeutic treatment with JNJ-49214689, starting one (Tx-1) 
or three (Tx-2) days post infection. Non-infected, vehicle-treated animals were indicated as 
No RSV. Assessed criteria were a) epithelial hyperplasia, b) peribronchiolar nodules, and c) 
perivascular nodules. JNJ-49214698 greatly reduces all assessed criteria in all treated lambs in 
comparison to the RSV-infected vehicle-treated lambs. Statistical analysis was performed by 
Kruskall-Wallis non-parametric test, followed by Dunn’s post-hoc test for multiple 
comparison correction. *p-value < 0.05; **p-value < 0.01; ***p-value < 0.001. 
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Summary 
Respiratory Syncytial Virus (RSV) infects individuals of all ages and can cause severe lower 
respiratory tract infection in infants and elderly. Given the burden of RSV disease and the lack of 
any vaccine or efficacious therapeutic intervention, the discovery of new antiviral compounds are 
in critically need. Therefore, the efficacy of RSV-NFI, a non-fusion RSV inhibitor, was tested for 
efficacy in this study in the neonatal lamb model. Five groups of lambs were used to test the 
efficacy of this compound at different concentrations. Three groups, TX1, TX2, and TX3, were 
treated with RSV-NFI 24hr after RSV inoculation and once daily with 16, 4, or 1 mg/kg body 
weight, respectively. The two other groups were treated with vehicle only after nebulization with 
RSV or mock media. All lambs were euthanized at day 6 post-infection, which corresponds to the 
expression of severe disease features in untreated animals. Pharmacokinetic analysis indicated that 
RSV-NFI reached a suitable plasma concentration within 24 hr after administration, and this level 
persist throughout the study that helped relate the plasma level to the antiviral efficacy.  All tested 
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doses drastically reduced the appearance of RSV-induced gross and microscopic lesions. There 
was a significant reduction in the viral load in the lung in both TX1 and Tx2 groups. Together; 
these results demonstrate efficacy of the RSV-NFI in reducing RSV infection and inhibiting RSV-
induced lung pathology.  
Introduction  
Respiratory Syncytial Virus (RSV) is a common respiratory virus in all ages and leads to 
moderate upper respiratory tract infection. However, RSV can progress to severe acute lower 
respiratory tract infection (ALRTI) in children under the age of five, older adults, and immune 
compromised individuals[1,2]. A systematic review and meta-analysis of RSV infection 
worldwide estimated that 2.4 million episodes of severe RSV associated ALRTI of 33.8 million 
total RSV infection each year[3]. Currently, there is no fully effective treatment or vaccine 
available for RSV infection.  
Recently, several antiviral compounds showed promising antiviral activity against RSV 
ALRTI and some of these have been approved for human clinical trials [4]. Only two approved 
treatments are commercially available including Palivizumab, which is a monoclonal antibody 
against RSV fusion protein administered as prophylaxis for preterm infants and high-risk 
individuals, and Ribavirin, a nucleoside analog antiviral drug [5,6].  Both of these compounds have 
limited indication and therapeutic efficacy [7–10]. Developing RSV antiviral drugs generally fall 
into three different categories: nucleoside inhibitors, fusion inhibitors, and non-fusion non-
nucleoside inhibitors [4]. A recent study with a fusion protein inhibitor indicated the possibility of 
treating existing RSV infection even after peak viral load and lung pathology and demonstrate a 
wide therapeutic intervention window for RSV [11].  
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Several models for RSV infection have been developed, and of these the neonatal lamb 
model has some characteristics similar to those in infants with RSV lower respiratory tract 
infection [12]. Lambs are susceptible to the human strain of RSV that causes moderate lower 
respiratory tract infection [13], have similar lung size, lung anatomy, and cellular composition of 
human infants, with similarity in immune responses and lung development. In this study, we 
evaluate the therapeutic efficacy of RSV-NFI, which is a non-fusion non-nucleoside RSV 
inhibitor, against RSV lower respiratory tract infection in the neonatal lamb model of RSV 
infection.  
Materials and Methods 
Experimental Design 
This study was completed in two parts in an experimentally identical environment. Animal 
use was approved by the Institutional Animal Care and Use Committee of Iowa State University.  
In the first part of the study, 2 high doses of RSV-NFI were tested with 4 experimental groups: 
RSV infected group; RSV (n=3) treated with vehicle only, TX1 (n=2) treated with RSV-NFI 
16mg/kg body weight and TX2 (n=4) treated with RSV-NFI 4 mg/kg body weight. The fourth 
group (n=4) infected with mock media and treated with vehicle to serve as a negative control 
group.  In the second part of the study, the efficacy of RSV-NFI low dose (1mg/kg body weight) 
was tested. 21 lambs were divided into 3 groups. There were two RSV infected groups: RSV (n=6) 
treated with vehicle only, and TX3 (n=7) treated with 1mg/kg RSV-NFI one day after viral 
nebulization, and a third group with no RSV (n=8) were nebulized with mock media and treated 
with vehicle only (Figure 1). Lambs were nebulized with 6 ml hRSV strain M37 (1.27 x 107 
Infectious Forming Unit (IFFU)/mL) on day 0. M37 is wild-type RSV A strain isolated from 
human infant and commercially provided by Meridian BioSciences (Memphis, TN, USA)[14,15]. 
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Treatments either with RSV-NFI or vehicle were started 24 hr after viral nebulization, then once 
daily for 5 days. Lambs were monitored daily for the presence of clinical signs, and then all lambs 
were humanely euthanized at day 6 post nebulization.  
Tissue and Sample Collection 
At necropsy (day 6 post nebulization), lambs were euthanized, and lungs were examined in 
situ, removed, and the percent of the lung with lesion were determined. Lung tissues were collected 
from right cranial, right middle, right caudal, and left cranial and placed in 10% neutral buffered 
formalin for histologic evaluation, or snap frozen in liquid nitrogen for qRT-PCR and 
pharmacokinetic study. Also, BALF samples were collected for left caudal lobe for infectious 
focus forming unit assay (IFFU) and RT-qPCR assays, and from left middle lobe for compound 
pharmacokinetic level assessment. 
Infectious Focus-Forming Unit (IFFU) Assay 
IFFU was completed on caudal lobe BALF, and homogenized lung tissue samples from the 
4 collected lung lobes, and assays were performed as previously described in our laboratory [16]. 
Briefly, samples were pelleted and resultant supernate was spin again through a 0.45 μm Costar 
SPIN-X filter (microcentrifuge 15,600 x g) for 5 minutes. The filtered samples were applied to 
70% confluent HEp-2 cells in a 12-well culture plates (Fisher Scientific, Hanover Park, IL) at full 
strength and three serial dilutions (1:10, 1:100, and 1:1000)in triplicate. After initial incubation at  
37°C, 5% CO2 for 1 hr, 1 mL of media was added to each well and plates were returned to the 
incubator and incubated for 48 hrs. plates, then, fixed with cold 60% acetone/40% methanol 
solution for 1 minute followed by immunofluorescent staining. Primary and secondary antibody 
were used. The primary was polyclonal goat anti-RSV (all antigens) antibody (EMD Millipore 
Corporation, Billerica, MA, USA), and the secondary antibody was (Alexa Fluor® 488 F(ab’)2 
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fragment of rabbit anti-goat IgG (H+L) (Molecular Probes/Life Technologies). Plates examined 
under inverted fluorescence microscopy using the FITX/GFP filter (Olympus CKX41, Center 
Valley, PA), and the total number of IFFUs (which is defined here as 3 or more fluorescing cells) 
were counted for each well. IFFU/mL calculations were obtained by multiplying the average 
number resulting from triplicate well counts by the initial BALF sample dilution factor and 
multiplying that value by 5 to obtain counts/mL since 1,000 μL/200 μl (the actual sample applied 
for each well) equals 5. 
Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) 
RSV RT-qPCR were completed on BALF and lung tissue. Lung samples from the 4 collected 
lung lobe were homogenized in TRIzol and extracted for total RNA according to the 
manufacturer's instruction. RNA samples were used for qRT-PCR as described previously[13,16–
18] to detect RSV, IP-10, MCP-1, MIP-1α, PDL-1, IFN-λ, IL-13, and RANTES mRNA 
expression. 
Histologic Evaluation 
Microscopic evaluation of the tissue section were completed with hematoxylin and eosin 
stained tissue sections, slides stained RSV antigen by immunohistochemistry, and slides processed 
by RSV RNAscope to detect RSV mRNA. In H and E sections, RSV lesions were scored on a 
scale of 0-4. These changes include bronchiolitis, syncytial cells, epithelial cells necrosis, 
epithelial cells hyperplasia, neutrophils, bronchiolar nodules, and perivascular nodules. Then an 
accumulative histological lesion score was determined by adding up the individualized score 
resulting in a score of 0-28 that represent the overall pathological changes in each tissue section 
(FI paper). Immunohistochemistry was completed on formalin fixed paraffin embedded tissue 
sections and as described previously [16,19,20]. Briefly, the slides were deparaffinized and 
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rehydrated; then antigen retrieval step were completed using PH 9 10mM TRIZMA base, 1mM 
EDTA buffer and 0.05 tween 20, then boiled and put in a steamer to maintain the temperature for 
at least 30 minutes. Tissues were blocked with 3% BSA and 20% NSS for 15 minutes each, 
followed by 1:500 dilution goat anti-RSV polyclonal antibody (Millipore/Chemicone Cat. No. 
AB1128) and incubated in 4C overnight. The next day, tissue were washed 3 times with TBS-tw 
followed by 1 hr incubation with 1:300 dilution of biotinylated Rabbit anti Goat secondary 
antibody (KP&L Cat. No. 16-13-06). After 3 washes with TBS-tw, tissue were incubated with 3% 
H2O2 for 25 minutes in room temperature followed by 2 TBS-tw washes and signal detection by 
incubation with 1:200 dilution streptavidin-horseradish peroxidase (Invitrogen Cat. No. 43-4323) 
followed by Nova Red staining solution. Slides were examined under light microscope and signal 
were quantified in both alveoli and bronchioles. Score of 0-4 were applied according to an integer 
based scale (of 0 = no positive alveoli/bronchioles, 1 = 1-10 positive alveoli/bronchioles, 2 = 11-
39 positive alveoli/bronchioles, 3 = 40-99 positive alveoli/bronchioles, 4 = >100 positive 
alveoli/bronchioles). The RNAscope assay was also done on FFPE tissue sections for the detection 
of RSV mRNA in situ by using a probe for RSV M37 nucleoprotein gene (Probe-V-RSV-NP, 
Advance Cell Diagnostic, Catalog number 439866). The assay were done as described previously 
( FI paper ) and according to the manufacturer protocol ((user manual document number 320497; 
RNAscope® 2.0 HD Detection Kit (BROWN) User Manual PART 2). Microscopic tissue sections 
were examined, and RNA signal were counted in both alveoli and bronchioles and applied for the 
same integer based scale used to assess the IHC, which is 0 = no positive alveoli/bronchioles, 1 = 
1-10 positive alveoli/bronchioles, 2 = 11-39 positive alveoli/bronchioles, 3 = 40-99 positive 




When appropriate and unless specified otherwise, due to the limited number of data 
observations in some treatment groups, the non-parametric Kruskal-Wallis test is applied to test 
whether there is difference between the compound groups and the vehicle group. P-values are 
adjusted with Bonferroni's multiple comparisons method. For the histological analysis of RSV 
antigen producing cells and for the histopathological analysis, treatment group at a value of zero 
were remove from the analysis (on/off patterns cannot be appropriately analyzed by statistics. 
However, this pattern indicates the presence of a treatment effect).  In the case of the histological 
analysis of RSV antigen producing cells, scores of at least 1 were recoded to 1 and logistic 
regression with random effects was applied for Slide and Animal to compare differences between 
treatment Tx3 and Vehicle. In the case of the histopathology analysis, scores of at least 1 are 
recoded to 1 and logistic regression with random effects for Animal was used to compare 
differences between treatments and Vehicle results 
Results 
Pharmacokinetics of Different Doses of RSV-NFI in the Neonatal Lambs 
Antiviral compounds need to reach an adequate and consistent exposure in the lung tissue in 
order to protect against multicyclic RSV infection. First, we assessed RSV-NFI levels in the 
plasma, then the compound distribution to the lung was evaluated. Compound absorption allowed 
a rapid increase in plasma exposure within 1 hr. Steady state was not reached at 24h probably due 
to the long half-life and slow elimination/metabolism of the compound. RSV-NFI plasma level at 
24 hr after the first dose were respectively :5902ng/ml (16 mg/kg group), 871ng/ml (4 mg/kg 
group), and 265ng/ml (1 mg/kg group:) with more than dose proportional increase of 5.0 and 4.6 
was observed when comparing 1 to 4 mg/kg doses and 4 to 16 mg/kg doses, respectively (Figure: 
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2a). Once-daily treatment with 1, 4 or 16 mg/kg of RSV-NFI lead to an increase of Ctrough over 
time across all different dose groups (3.6 fold at 1 mg/kg, 3.5 fold at 4 mg/kg, and 3.0 fold at 16 
mg/kg). At necropsy, the RSV-NFI concentration was measured in both BALF representing the 
airway lumen/ secretion, and in the whole lung homogenate representing lung tissue (cells, 
interstitial tissue, and vasculature). The compound exposure in bronchoalveolar lavage fluid 
(BALF) and homogenized-lungs tissue were the highest in the 16 mg/kg group (24431ng/ml, 
36213ng/g, respectively). BALF exposure in 4 and 1 mg/kg group was (2091 ng/ml, 299 ng/ml, 
respectively), and in the lung were (9740 ng/g, 2650 ng/g, respectively) (Figure 2 b & c). 
Subsequently, lung/ plasma ratio of 1.3, 0.9, 0.9 in animal treated with 1, 4, and 16 mg/kg, 
respectively, indicating a dose-dependent distribution of the compound to the lung compartments 
and optimal conditions for investigating therapeutic exposure levels. 
 Viral Load in BALF and Lavaged-Lung Samples of Neonatal Lambs 
The viral titer was determined at day 6 post-infection in BALF and homogenized lung tissue 
samples from animals that were treated once-daily as from Day 1 post-infection with either vehicle 
or different concentrations of RSV-NFI by the IFFU assay. There was a strong concentration-
dependent decrease of the production of infectious virions in BALF with 1.5 log10 reduction at 1 
mg/kg, 4.2 log10 reduction at 4 mg/kg (p<0.01), and 4.5 log10 reduction at 16 mg/kg(p<0.01) (Figure 
3 a). Concomitantly, lung titers of infectious virions were drastically reduced in all compound 
treated groups. There was a 2.0 log10 reduction in the viral titer in 1 mg/kg treated group(p<0.01), 
while full effect of 2.2 log10 reduction in groups treated with 4, and 16 mg/kg (p<0.01) & (p<0.05), 
respectively (Figure 3b). To assess whether the reduction in the viable viral particle was 
accompanied by a reduction in the viral RNA, a qRT-PCR was done on the same BALF samples 
and lung tissues representative from four lung lobes. There was a great reduction in viral RNA 
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copies in both BALF and lung (Figure 3c and 2d). There was a significant 1.4 log10 decrease in 
viral RNA at 1 mg/ml in BALF (p<0.0001) accompanied by 1 log10 reduction lung tissue. Superior 
effects were observed at 4 mg/kg and 16 mg/kg treatment as is shown by 2.8 log10 reduction in 
BALF(p<0.0001), accompanied by 4.4 log10 and 4 log10 reduction in lung tissue, respectively 
((p<0.001) (p<0.0001) respectively). These results prove that the compound was efficient in 
reducing the viral load in the treated lambs. 
Treatment with RSV-NFI Significantly Reduced RSV-Induced Lung Lesion  
Six days after infection, lungs from animals across different study groups were removed, and 
the gross lesion developed by the lung upon RSV infection were scored. The RSV gross lesion 
which was prominent in the RSV infected vehicle-treated group characterized by multifocal dark 
red areas of consolidation on the lung surface and extend deep into the lung parenchyma in cut 
section. In lungs of non-infected vehicle-treated animals, no gross lesions compatible with RSV 
infection was seen. In contrast, in infected vehicle-treated animals, a significant level of the lung 
surface area (32% on average) had gross lesions compatible with RSV infection (Figure 4 a and 
b). Treatment with different doses of RSV-NFI drastically reduced the level of gross lesions 
observed in all treated group when compared to the RSV infected vehicle-treated group. Gross 
lesions were decreased to 0.76 % (p<0.05) or 0% (p<0.01) of lung surface when animals were 
treated with 1 mg/kg or higher doses (4 and 16 mg/kg), respectively (Figure 4 a and b).  
Microscopically, different concentrations of RSV-NFI resulted in a drastic reduction of all 
assessed parameters and subsequently the accumulative histopathologic lesion score. The 
histopathological lesion observed in the RSV infected vehicle-treated group was severe interstitial 
pneumonia with bronchiolitis. There was inter-alveolar wall thickening due to inflammatory cell 
infiltration, and epithelial cell hyperplasia with occasional necrotic epithelial cells and syncytia 
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formation leading to an accumulative histopathologic score of 11 (figure 5 a and b and figure 8). 
The compound treatments significantly reduce the accumulative histopathologic lesion score in all 
treated group (P<0.01) (Figure 5 a and b). 16 mg/kg reduced the accumulative histopathologic 
score to 0.12, while 4mg/k and 1mg/kg treatments reduced the accumulative histopathologic score 
to 0.6 and 1.2 (Figure 5 a and b). To further evaluate the degree of RSV infection in the lung tissue, 
RSV immunohistochemical stain was done on FFPE tissue sections.  RSV M37 antigen 
demonstrated a dose-dependent decrease in the density of M37 antigen in the different lung lobes. 
No RSV antigen detected in animals treated with 4 and 16 mg/kg (P<0.01 and P<0.05, 
respectively) (Figure 6 a). There was a significant decrease in the RSV antigen expression in 
bronchioles of animal treated with the low dose RSV-NFI (1 mg/kg)(p<0.05), with a high 
reduction in the alveoli (P=0.059) indicating the efficiency of treatment with the study compound 
to reduce RSV dissemination. Similar to what found in qRT-PCR of the BALF and lung tissue, 
there was a significant reduction in RNA expression in situ in all RSV-NFI treated groups (P<0.01) 
(Figure 7 b) as tested by RNAscope technique. The compound treatment drastically reduces RSV 
mRNA in all treated groups with the most reduction was in 16 and 4 mg/kg treatment. Hence, the 
RSV-NFI showed a strong effect in reducing RSV antigen and mRNA and subsequently RSV 
associated lung lesion. 
Treatment with RSV-NFI Significantly Decrease Inflammatory Chemokines 
By qRT-PCR in lung at day 6 p.i. RSV-NFI greatly reduce mRNA expression of IP-10, MCP-
1, MIP-1α, PDL-1, and IFN-λ in comparison to the RSV infected vehicle-treated group in which 
the expression of these chemokines were elevated (Figure 9 a-e). There was no difference shown 




Given the burden of RSV infection in infant and elderly, the development of active anti-RSV 
therapeutic is urgently needed. Several antiviral drugs that target RSV have reached advanced 
clinical trials. Most of these antiviral drugs are f monoclonal antibodies that inhibit fusion [4]. 
However, RSV resistant mutants can potentially form after few passages [21] and thus, additional 
antiviral compounds with different mode of action that targets other viral structural component is 
needed.  In this study, we evaluate a non-fusion RSV inhibitor RSV-NFI, which is a non-
nucleoside replication inhibitor, in the neonatal lamb model. This study aims to assess the 
therapeutic effect of different doses of RSV-NFI on established RSV associated acute lower 
respiratory tract infection with treatment started one day after the viral nebulization and repeated 
once daily up to 5 days. Our results demonstrated a potent antiviral activity as reflected by reduced 
viral titer, mRNA expression, and RSV associated lesions in infected lambs.   
Different concentrations of the compound resulted in different plasma exposure with more 
than dose proportional when comparing each treatment with the one higher. However, the plasma 
exposure was stable throughout the study with a tendency to increase over time. All the treatment 
groups reached a concentration above the EC90 after 24 hr post-treatment except for 1mg/kg 
treatment group which reached a concentration above the EC90 48hr after the first dose. This 
plasma concentration leads to adequate lung exposure (at day 6 post-infection) which reflect the 
concentration pattern seen in the plasma, i.e., high dose group produced a higher RSV-NFI 
concentration in the lung tissue. Consistent RSV-NFI presence in the lung gives the compound the 
ability to act on each new viral cycle reducing the RSV replication and cellular reinfection. 
Lambs are permissive for hRSV and the human strains replicates well in lambs airways 
causing acute lower respiratory tract infection [19,20,18,22]. Lambs nebulized with hRSV have 
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the peak viral load by day 3 of infection with the most lung lesions developing at day 4 to 6 post 
nebulization [16]. RSV infected and vehicle-treated lambs in this study had high infective virus 
and mRNA levels with distinct lesions in lung tissue characterized by interstitial pneumonia and 
bronchiolitis. In contrast, treatment with different concentrations of RSV-NFI resulted in 
consistent and significant reductions of all the assessed endpoints such as the reduction of lung 
viral titers as measured by IFFU assay or qRT-PCR and reduced RSV associated lung lesions. The 
results of both IFFU and qRT-PCR indicate the presence of viable RSV and whole viral load, 
respectively, and were consistent and had the same pattern in BALF and lung tissue, and both had 
a great reduction in the viral load with treatment that correlated with the RSV-NFI concentration. 
Treatment with RSV-NFI as low as 1mg/kg caused a drastic reduction in the viral load in lung. 
However, the most pronounced reduction occurred in 4 and 16 mg/kg groups. Several studies 
indicated the positive relation between viral load and disease severity in infant [23–25]. Thus, the 
observed reduction in the viral load in this study predicted to have a substantial effect in reducing 
the pathological lesions associated with RSV by giving the lambs the ability to respond and repair 
the tissue damage. 
RSV associated gross and microscopic lesions were significantly decreased in all treated 
animals. Almost no RSV lesions were seen at day 6 post-infection in the 4 and 16 mg/kg groups 
with a great decline the lesions in the 1 mg/kg treated group. These results were consistent with 
RSV immunohistochemistry and RNAscope results that had similar reduction trend in RSV 
antigen and RSV RNA expression. Additionally, the increased inflammatory cell infiltration in 
lung tissue of RSV infected vehicle treated lambs were accompanied by elevated level of MCP-1 
and MIP-1α, and consistent with an earlier study in lamb indicated increase level of these 
chemokines in RSV infected lambs at day 6 p.i. [18].  Several studies on RSV lower respiratory 
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tract infection in infants indicated that elevated levels of IP10, MIP-1α, and MCP-1 act as a 
chemoattractant for inflammatory cells and subsequently associated with severe bronchiolitis and 
hospitalization [26,27]. In contrast, an elevated level of PDL-1 in RSV infected vehicle treated 
lambs may suggest a vital role in inhibiting lymphocytes antiviral response by modulating PDL-1 
expression in infected epithelial cells [28,29]. The presence of minimal RSV antigen and mRNA 
in the lung tissue section of the treated group indicate the ability of RSV-NFI to halt RSV 
replication and infection of adjacent cells. 
In summary, the compound under investigation had a strong effect on reducing RSV viral 
load and lesions in all treated groups in comparison to the RSV infected vehicle-treated group. 
This strong treatment effect occurred even when RSV-NFI was delivered to lambs one day after 
viral nebulization, indicating the efficacy of the compound as a post infection therapeutic modality 
to decrease the severity of lower respiratory tract infection after established RSV infection.  
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Figures and Legends 
 
Figure 4-1:Experimental design. 
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Figure 4-2: Exposure of RSV-NFI in different body compartments. 
 a) RSV-NFI daily plasma concentration (ng/ml) 24 hr post-treatment. RSV-NFI concentration in BALF 
(b) and homogenized lung tissue (b) at day 6 post-infectionShownwn as average+ SEM. The compound 
reached a steady state concentration in the plasma and accumulated over time with subsequent high 
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Figure 4-3: Effect of RSV-NFI on viral titer in BALF and lung tissue homogenates at day 6 
p.i. 
a and b show the infectious viral titer as measured by IFFU assay in BALF (a) and in lung tissue (b). c and 
d show the RSV mRNA titer as measured by qRT-PCR in BALF (c) and in lung tissue (d)All shown as 
individual titer and mean.  Treatment with RSV-NFI reduces the infectious viral titer and RNA in BALF 
and Lung tissue. Animal infected with RSV and treated with either vehicle only (0) or different 
concentration of RSV-NFI (1, 4, 16 mg/kg). Baseline lambs are not infected and treated with vehicle only. 


























a) Show the average % of lung tissue parenchyma involved with RSV gross lesion shown as individual % 
and mean. b) Shows picture representative of gross lesion observed in different treatment group. RSV-NFI 
greatly prevent the development of RSV associated gross lesion. Animal infected with RSV and treated 
with either vehicle only (0) or different concentration of RSV-NFI (1, 4, 16 mg/kg). Baseline lambs are not 






















































































 a) the accumulative histological lesion associated with RSV infection, which represents the sum of lesions 
scored in RSV infected lung tissue which includes Bronchiolitis, Syncytial cells, Epithelial cells necrosis, 
epithelial cells hyperplasia, neutrophils, Bronchiolar nodules, and perivascular nodules. b) a photo 
representative for each treatment group. RSV-NFI greatly reduced the RSV associated microscopic lesion 
in lung tissue. Animal infected with RSV and treated with either vehicle only (0) or different concentration 
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 a) integer-based scoring of RSV M37 antigen in lung tissue detected by IHC had as average + SEM. 
Treatment with RSV-NFI greatly reduces RSV antigen expression in lung tissue. b) shows photo 
representation antigen distribution from different treatment group.  Lung from lamb infected with RSV and 
treated with either vehicle only (0) or different concentration of RSV-NFI (1, 4, 16 mg/kg). Baseline lambs 
are not infected and treated with vehicle only. Estimated odds ratios: ***p<0.001. $: on/off pattern 
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a) integer-based scoring of RSV M37 RNA in lung tissue detected by RNAscope had as average + SEM. 
Treatment with RSV-NFI greatly reduces RSV RNA expression in lung tissue. b) Picturesdepict findings 
representation from different treatment group.  Animal infected with RSV and treated with either vehicle 
only (0) or different concentration of RSV-NFI (1, 4, 16 mg/kg). Baseline lambs are not infected and treated 
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Figure 4-7: Effect of RSV-NFI on RSV M37 RNA expression. 
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Figure 4-8: Effect of RSV-NFI on the development of RSV associated histologic lesion. 
Graphs show an integer-based score of Bronchiolitis (a), Syncytial cells (b), Epithelial cells necrosis (c), 
epithelial cells hyperplasia (d), neutrophils (e), Bronchial nodules (f), and perivascular nodules (g) RSV-
NFI greatly reduce the RSV associated microscopic lesion in lung tissue. Animal infected with RSV and 
treated with either vehicle only (0) or different concentration of RSV-NFI (1, 4, 16 mg/kg). Baseline lambs 
are not infected and treated with vehicle only. *p<0.05, **p<0.01, ***p<0.001,****p<0.0001. n.s.: not 
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Figure 4-9: Effect of RSV-NFI inflammatory chemokine RNA expression in lung tissue. 
Chemokine RNA expression IP-10 (a), MCP-1 (b),  MIP-1α (c), PDL-1 (d), INF-λ (e), IL-13 (f), RANTES 
(g). All are shown as average + SEM. Treatment with RSV-NFI greatly reduces IP-10, MCP-1, MIP-1α, 
PDL-1, INF-λ. Animal infected with RSV and treated with either vehicle only (0) or different concentration 
of RSV-NFI (1, 4, 16 mg/kg). Baseline lambs are not infected and treated with vehicle only. *p<0.05, 





CHAPTER 5. GENERAL CONCLUSION 
Secondary Bacterial Co-Infection 
The neonatal lamb model of RSV infection is well established, and many aspects of the 
model were investigated in our laboratory such as different viral strains, different viral cultures, 
different inoculation techniques, viral kinetics, immune response, and associated clinical signs [1–
6]. Investigating mechanisms of bacterial infections secondary to RSV infection is the next step to 
understand the pathogenesis of bacterial coinfection and utilize the model to test the efficacy of 
therapeutic agents in complex infections which are associated with enhanced disease severity and 
death.  This study demonstrated the susceptibility of lamb to Streptococcus pneumoniae (Spn) 
infection, and the enhanced disease severity when lambs challenged with Spn 3 days after primary 
RSV nebulization in comparison to lambs receiving either RSV or Spn alone.  The titer of RSV 
were higher in the RSV-Spn infected group than RSV alone, while there were no differences 
between Spn infected lambs in Spn lung titer.  There was an increase in severity of lung lesions in 
the RSV-Spn group, which was characterized by a higher number of infiltrating neutrophils, and 
increased epithelial necrosis and degeneration. These findings were in agreement other studies of 
viral-bacterial co-infection, and demonstrated the enhanced infection by both pathogens.  
 
Efficacy of Anti-RSV Fusion Inhibitor 
The neonatal lamb model of RSV infection which mimics RSV infection in infants provides 
an excellent tool to evaluate the efficacy of antiviral compound on the development of RSV-
associated acute lower respiratory tract infection.  This study demonstrated the efficacy of JNJ-
49214698, which is an RSV small molecule fusion inhibitor that binds to the RSV prefusion 
conformation preventing critical F protein transformation to postfusion conformation and 
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subsequently preventing multicyclic RSV infection.  In three treatment regimen,JNJ-49214698 
had a very protective effect when given prophylactically 1 day before RSV nebulization.  These 
lambs had no infectious RSV or mRNA in the lung, and had minimal clinical signs, and almost no 
RSV associated lung lesion.  Although prophylactic administration of JNJ-49214698 is not its 
intended use, the finding demonstrates  the ability of fusion inhibitor to prevent RSV infection. 
When JNJ-49214698 given 1 day and 3 days post-RSV nebulization, it had significant decrease in 
infectious RSV in the BALF with a less pronounced reduction in the mRNA.  There were 
reductions in RSV associated clinical signs, gross and microscopic lung lesion, and RSV protein 
and mRNA expression in lung tissue.  The effect of JNJ-49214698 was more evident when given 
1 day after RSV nebulization. These data suggest a protective effect of JNJ-49214698 in reducing 
RSV replication and subsequently RSV associated signs and lesions.  Therefore, the compound is 
a promising  antiviral candidate against RSV infection in infants.  
 
Efficacy of Anti-RSV Non-Fusion Inhibitor 
Another mechanistic type of anti-RSV compounds are the non-fusion inhibitors, which bind 
and inhibit viral structural protein other than F protein.  In this study, we evaluated the efficacy of 
the non-fusion inhibitor JNJ-64417184 in the neonatal lamb model of RSV infection. In this study, 
3 different doses were used to treat lambs 1 day after RSV nebulization (16, 4, or 1 mg/kg body 
weight).  The study demonstrated that JNJ-64417184 markedly reduced all RSV associated lesions 
in treated lambs in comparison to RSV infected vehicle-treated lambs. Additionally, the compound 
significantly reduced infectious RSV titer and mRNA expression in BALF and lung tissue 
homogenate and markedly reduced RSV antigen and mRNA expression in lung tissue sections.  
These results were accompanied by a reduction in immunomodulatory cytokines IP-10, MCP-1, 
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MIP-1α, PDL-1, and IFN-λ, and correlated with the reduction of inflammatory cells in the lung 
tissue observed in histological evaluation.  These results indicate the ability of JNJ-64417184 to 
reduce RSV replication and disease progress.  
Future Directions  
The neonatal lamb model of RSV infection in infants is a well-characterized model and 
currently used to evaluate anti-RSV therapeutics[7,8].  We demonstrated that neonatal lambs 
infected with RSV are also susceptible for infection with Spn and lead to enhance disease severity 
in lambs infected with both RSV-Spn.  Several aspects of this model can be modified and further 
developed in future studies of viral-bacterial co-infection such as: expanding the length of time of 
infection,  assessing different inoculation time points of Spn following RSV, assessing different 
doses of Spn, and different types of Spn delivery (e.g., intranasal, intrabronchial, aerosolization).  
Also regarding Spn, a colonization model similar to human and mice could be tested to evaluate 
whether such mechanism of infection is a possibility in the lamb model. A third consideration is 
to try assess other bacterial pathogens or combinations of:Staphylococcus aureus, Streptococcus 
pyogenes, and Haemophilus influenza.  These three bacterial pathogens are the most common 
bacteria identified secondarily to viral infections in human.  
Several characteristics make the neonatal lamb model an interest and compelling option for 
pharmaceutical companies to assess their compounds.  Although our laboratory has inoculated 
lambs by various routes including intra-tracheal, bronchoscopy guided intra-bronchial inoculation, 
nebulization of the virus has several advantages [2,5,6]. RSV nebulization provides more 
homogenous distribution of the virus to different lung lobes and subsequently homogenized lung 
pathology[5,9]. RSV nebulization is one feature of the neonatal lamb model that provides 
consistency for RSV associated lower respiratory tract infection and does overwhelm areas of RSV 
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infection as can occur with intrabronchial deposition. We demonstrated that two antiviral 
compounds which  target fusion protein (entry of the virus) and non-fusion protein (replication of 
the virus) had a strong effect in reducing RSV replication and associated pathology.  In this same 
fashion, other viral targets could be tested in the lamb model such as RSV N, SH, and L proteins.  
Other potential studies could include a combination of compound that target 2 or more RSV protein 
and different time points for treatment administration. However, treating within 2 days post viral 
inoculation may be ideal because this likely is the time an infant may seek medical 
intervention[10].  
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